US Pat. No. 10,688,411

POROUS MOLDING, GEL MOLDING AND FILTER

3M Innovative Properties,...

1. A porous molding that is achieved by sintering a mixed powder including dried gel powder and thermoplastic resin powder, wherein:a ratio of an average particle diameter d2 of the dried gel powder to an average particle diameter di of the thermoplastic resin powder d2/d1 is 1.3 or more, and
d3 is an average particle diameter of the dried gel powder when absorbing water and swelling, wherein (d3-d2)/d1 is 4.0 or less, and wherein the porous molding is self-supportable before and after the dried gel powder absorbs water and swells.
US Pat. No. 10,689,436

HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ

REGENERON PHARMACEUTICALS...

1. An isolated antibody or antigen-binding fragment thereof, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) comprising the amino acid sequence set forth in SEQ ID NO: 50; and three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) comprising the amino acid sequence set forth in SEQ ID NO: 66.
US Pat. No. 10,689,693

METHOD AND MEANS FOR DIAGNOSING TUMORS

1. Method for amplifying and quantifying DNA in an isolated sample, comprising the steps of:a) bisulphite conversion of the DNA in the sample,
b) pre-amplifying methylated and unmethylated DNA sequences by means of PCR, wherein the methylated DNA sequences are amplified to a different extent than the unmethylated DNA sequences,
c) quantifying the methylated and unmethylated DNA obtained in step b) by means of digital PCR, wherein the average number of DNA molecules per compartment used in the digital PCR is at least 8.
US Pat. No. 10,688,156

METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS

PHASEBIO PHARMACEUTICALS,...

1. A method for treating or delaying the progression of muscular dystrophy comprising administering to a patient in need thereof a pharmaceutical composition comprising a VPAC2-selective Vasoactive Intestinal Peptide (VIP) and an elastin-like peptide comprising at least 90 repeating units of VPGXG (SEQ ID NO: 3), where X is independently selected from Val, Ala, and Gly at a ratio of about 5:3:2.
US Pat. No. 10,688,412

AFFINITY CHROMATOGRAPHY WASH BUFFER

Cehpalon, Inc., Frazer, ...

1. A method of preparing a purified protein of interest, comprising loading a mixture comprising a protein of interest and one or more contaminant proteins onto an affinity chromatography ligand, washing the ligand with an aqueous wash solution comprising arginine and guanidine to elute the one or more contaminant proteins from the ligand, and then eluting the protein of interest from the ligand, thereby forming a purified eluate of the protein of interest, wherein the protein of interest is an antibody.
US Pat. No. 10,689,437

RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF

MedImmune, LLC, Gaithers...

1. An antibody or a functional part thereof capable of specifically binding the Respiratory Syncytial Virus (RSV) F protein, the antibody or functional part thereof comprising the heavy and light chain variable region CDRs 1-3 encoded by the 1G7-containing vector deposited at the ATCC under Patent Designation PTA-125140.
US Pat. No. 10,689,694

METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS

Life Technologies Corpora...

1. A reaction mixture comprising:a) a first sample of amplicons, wherein said sample of amplicons is generated by multiplex pre-amplification of a nucleic acid sample;
b) an allele-specific primer, wherein an allele-specific nucleotide portion of the allele-specific primer is complementary to a first allelic variant of a target sequence;
c) an allele-specific blocker probe that is complementary to a region of the target sequence comprising a second allelic variant, wherein said region encompasses a position corresponding to the binding position of the allele-specific nucleotide portion of the allele-specific primer, and wherein the allele-specific blocker probe comprises a minor groove binder;
d) a locus-specific primer that is complementary to a region of the target sequence that is 3? from the first allelic variant and on the opposite strand; and
e) a detector probe.
US Pat. No. 10,690,207

FRICTION MATERIAL

AKEBONO BRAKE INDUSTRY CO...

1. A friction material comprising:a. at least one lubricant, wherein the at least one lubricant includes an amount of graphite, and wherein at least about 30 percent by weight of the graphite has a particle size of greater than about 500 microns using a sieve analysis;
b. at least one metal containing constituent for imparting reinforcement, thermal conductivity, and/or friction when the friction material is brought into contact with a movable member, wherein the at least one metal containing constituent includes iron and an iron containing compound;
c. a micro-particulated material that is a compound including molybdenum and oxygen, wherein the micro-particulated material resists corrosion of the at least one metal containing constituent;
d. one or more filler materials;
e. optionally at least one processing aid;
f. a balance being an organic binder;
g. wherein the friction material is free of asbestos and substantially devoid of copper.
US Pat. No. 10,688,157

TRUNCATED VON WILLEBRAND FACTOR POLYPEPTIDES FOR TREATING HEMOPHILIA

CSL BEHRING LENGNAU AG, ...

1. A method of treating a blood coagulation disorder, comprising administering to a subject in need thereof an effective amount of (1) a polypeptide comprising a truncated von Willebrand Factor (VWF) and (2) a Factor VIII (FVIII), wherein the subject has endogenous VWF, wherein the polypeptide is capable of binding to the FVIII, and wherein(i) the molar ratio of the polypeptide to the FVIII is greater than about 50, and/or
(ii) the molar ratio of the polypeptide to the endogenous VWF in the subject's plasma, immediately after administration of the polypeptide, is greater than about 0.5;
wherein the truncated VWF comprises amino acids 764 to 1242 of SEQ ID NO:4.
US Pat. No. 10,689,438

STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

Novartis AG, Basel (CH)

1. An aqueous ophthalmic pharmaceutical composition, comprising (i) at least 60 mg/ml of an anti-VEGF antibody that comprises the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, (ii) about 6.75% (w/v) sucrose, (iii) a citrate buffer comprising about 0.01% (w/v) citric acid and about 0.428% (w/v) trisodium citrate dehydrate, and (iv) about 0.05% (w/v) polysorbate 80 as a surfactant, wherein the maximum number of particles ?10 ?m diameter in the aqueous ophthalmic pharmaceutical composition is 50 per mL.
US Pat. No. 10,689,695

MULTIPLEX AMPLIFICATION OF POLYNUCLEOTIDES

Applied Biosystems, LLC, ...

1. A kit for carrying out a two-step amplifications reaction comprising:(a) a first container or reaction vessel comprising a plurality of amplification primer sets suitable for carrying out a multiplex amplification reaction to produce a plurality of different amplicons and one or more single-stranded oligonucleotide probes complementary to all or a part of one or more of the plurality of different amplicons; and
(b) a second container or reaction vessel comprising a single set of amplification primers suitable for carrying out a singleplex amplification reaction to produce a single amplicon, and a single-stranded oligonucleotide probe complementary to all or a part of the single amplicon.
US Pat. No. 10,688,158

COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MILK THISTLE EXTRACT OR POWDER

NUTRAMAX LABORATORIES, IN...

1. An orally administrable composition comprising a synergistic combination of a broccoli extract or powder and a milk thistle extract or powder.
US Pat. No. 10,689,439

OPTIMIZED ANTI-TL1A ANTIBODIES

Prometheus Biosciences, I...

1. An antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1A (TL1A), comprisinga heavy chain variable region comprising: (a) a HCDR1 comprising the amino acid sequence set forth by SEQ ID NO: 553; (b) a HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 554 to 564 or 574 to 577; and (c) a HCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 565 to 568 or 579 to 581; and
a light chain variable region comprising: (d) a LCDR1 comprising an amino acid sequence set forth by any one of SEQ ID NOs: 569 or 570; (e) a LCDR2 comprising the amino acid sequence set forth by SEQ ID NO: 488; and (f) a LCDR3 comprising the amino acid sequence set forth by SEQ ID NO: 572.
US Pat. No. 10,689,696

METHODS AND SYSTEMS FOR ANALYZING IMAGE DATA

ILLUMINA, INC., San Dieg...

1. A method comprising:(a) performing a plurality of cycles of a sequencing by synthesis reaction such that, at each cycle, a signal is generated that is indicative of incorporation of a same nucleotide into a plurality of identical polynucleotides, whereby a portion of the signal is noise associated with phasing or pre-phasing;
(b) detecting the signal at each cycle in at least one channel, wherein the signal at each cycle includes an intensity value for each channel; and
(c) preforming cycle-by-cycle phasing corrections by applying a new first order phasing correction at each cycle to the intensity value for each channel;
wherein the new first order phasing correction is calculated for each channel of each cycle, wherein the new first order phasing correction includes subtracting an intensity value of an immediately previous cycle from an intensity value of a current cycle and also includes subtracting an intensity value of an immediately subsequent cycle from the intensity value of the current cycle; and
wherein the same nucleotide incorporated into the plurality of identical polynucleotides is identified for each cycle.
US Pat. No. 10,688,159

COMPOSITIONS AND KITS FOR TREATING PRURITUS AND METHODS OF USING THE SAME

ROCHAL INDUSTRIES, LLC, ...

1. A method of ameliorating a sensation of itching, the method comprising:topically administering a therapeutically effective amount of an enzymatic pruritic composition to itching tissue,
wherein said enzymatic pruritic composition comprises:
0.10 to 99.5% by weight of an amylase component,
wherein the amylase component comprises an amylase selected from the group consisting of non-human animal amylase, bacteria amylase, plant amylase, fungi amylase, and recombinant amylase, and
at least one pharmaceutically or cosmetically acceptable carrier or excipient in an amount of up to 99.9% by weight,
wherein the percentages are based on a total weight of the enzymatic pruritic composition,
wherein, if a proteolytic enzyme component is present in the enzymatic pruritic composition, then the amylase component and proteolytic enzyme component are present in a weight ratio of at least 10:1; and
wherein the itching tissue is selected from the group consisting of rashes, dry skin, pimples, contact dermatitis, psoriasis, rosacea, seborrheic dermatitis, insect bites, acne, cysts, blisters, chemical irritants, biological irritants, sunburn, and frostbite.
US Pat. No. 10,689,697

ANALYSIS OF A POLYMER

Oxford Nanopore Technolog...

1. A method of controlling a biochemical analysis system for analyzing polymers that comprise a sequence of polymer units, wherein the biochemical analysis system comprises at least one sensor element that comprises a nanopore, and the biochemical analysis system is operable to take successive measurements of a polymer from a sensor element, during translocation of the polymer through the nanopore of the sensor element,wherein the method comprises, analyzing a series of measurements taken from between 30 and 250 nucleotides of the polymer as the polymer partially translocates through the nanopore, using reference data derived from at least one reference sequence of polymer units to provide a measure of similarity between the sequence of the 30 to 250 nucleotides of the partially translocated polymer and the at least one reference sequence, and
responsive to the measure of similarity, operating the biochemical analysis system to reject the partially translocated polymer to end analysis of the polymer and to take measurements from a further polymer;
wherein the polymer is a first polynucleotide, the further polymer is a second polynucleotide, and the polymer units are nucleotides;
wherein
the measurements are dependent on a k-mer, being k polymer units of polymer, where k is an integer;
the reference data represents a reference model that treats the measurements as observations of a reference series of k-mer states corresponding to the reference sequence of polymer units, wherein the reference model comprises:
transition weightings for transitions between the k-mer states in the reference series of k-mer states; and
in respect of each k-mer state, emission weightings for different measurements being observed when the k-mer state is observed, and
said step of analyzing the series of measurements taken from the about 30 nucleotides of the polymer during the partial translocation comprises fitting the model to the series of measurements to provide the measure of similarity as the fit of the model to the series of measurements.
US Pat. No. 10,688,160

ENZYMES AND METHODS FOR CLEAVING N-GLYCANS FROM GLYCOPROTEINS

The Regents of the Univer...

1. A composition comprising released N-glycans, wherein the released N-glycans are generated by contacting a glycoprotein with a GH18 endoglycosidase comprising SEQ ID NO:1, wherein high mannose glycans, complex glycans, hybrid N-glycans, or a combination thereof are released from the glycoprotein, wherein the GH18 endoglycosidase comprises an amino acid sequence at least 90% identical to SEQ ID NO:4 or SEQ ID NO:5.
US Pat. No. 10,689,441

ANTI—TLR4 ANTIBODIES AND METHODS OF USE THEREOF

NovImmune SA, Geneva (CH...

1. A method of preventing or reducing the likelihood of Graft-versus-Host disease (GvHD) in a human subject in need of an allogeneic stem cell transplant comprising:(i) contacting a stem cell population that is allogeneic to said human subject with an antibody or immunologically active fragment thereof that specifically binds a human Toll-like receptor 4 (TLR4) polypeptide comprising a variable heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of GGYSWH (SEQ ID NO: 1); a VH CDR2 region comprising the amino acid sequence of YIHYSGYTDFNPSLKT (SEQ ID NO: 2); a VH CDR3 region comprising the amino acid sequence of KDPSDAFPY (SEQ ID NO: 3); a variable light chain complementarity determining region 1 (VL CDR1) region comprising the amino acid sequence of RASQSISDHLH (SEQ ID NO: 4); a VL CDR2 region comprising the amino acid sequence of YASHAIS (SEQ ID NO: 5); and a VL CDR3 region comprising the amino acid sequence of QQGHSFPLT (SEQ ID NO: 6), to produce a transplantable composition; and
(ii) implanting the transplantable composition at a desired location in the subject.
US Pat. No. 10,688,161

MITRECIN A POLYPEPTIDE WITH ANTIMICROBIAL ACTIVITY

The MITRE Corporation, M...

1. A method of ameliorating or treating a disease or disorder in a plant, the method comprising contacting the plant with a formulation comprising an effective amount of an isolated polypeptide comprising amino acids 54 to 73 of SEQ ID NO:2 and said polypeptide has at least 90% sequence identity to SEQ ID NO: 2, wherein contacting the plant with the formulation ameliorates or treats the disease or disorder in the plant, and wherein the disease or disorder is caused by a Gram negative bacteria.
US Pat. No. 10,689,442

ANTIBODIES AGAINST FRIZZLED RECEPTOR

Sachdev Sidhu, Toronto (...

1. An isolated antibody or antigen-binding fragment thereof that binds to one or more Frizzled receptors and prevents the one or more Frizzled receptors from binding to a Wnt protein ligand, wherein the antibody or antigen-binding fragment thereof comprises:a) a variable light chain complementarity determining region 1 (CDRL1) comprising an amino acid sequence of SEQ ID NO: 392;
b) a variable light chain complementarity determining region 2 (CDRL2) comprising an amino acid sequence of SEQ ID NO: 393;
c) a variable light chain complementarity determining region 3 (CDRL3) comprising an amino acid sequence of SEQ ID NO: 132;
d) a variable heavy chain complementarity determining region (CDRH1) comprising an amino acid sequence of SEQ ID NO: 133;
e) a variable heavy chain complementarity determining region (CDRH2) comprising an amino acid sequence of SEQ ID NO: 134; and
f) a variable heavy chain complementarity determining region (CDRH3) comprising an amino acid sequence of SEQ ID NO: 135.
US Pat. No. 10,689,699

METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING

UNIVERSITY OF WASHINGTON ...

1. A method, comprising:a) providing a population of circulating DNA molecules obtained from a bodily sample from a subject;
b) converting the population of circulating DNA molecules into a population of non-uniquely tagged parent polynucleotides, wherein each of the non-uniquely tagged parent polynucleotides comprises (i) a sequence from a circulating DNA molecule of the population of circulating DNA molecules, and (ii) an identifier sequence comprising one or more polynucleotide barcodes, such that each non-uniquely tagged parent polynucleotide is substantially unique with respect to other non-uniquely tagged parent polynucleotides in the population;
c) amplifying the population of non-uniquely tagged parent polynucleotides to produce a corresponding population of amplified progeny polynucleotides;
d) sequencing at least a portion of the population of amplified progeny polynucleotides to produce a set of sequence reads;
e) grouping the sequence reads into families, each of the families comprising sequence reads comprising the same identifier sequence and having the same start and stop positions, whereby each of the families comprises sequence reads amplified from the same non-uniquely tagged parent polynucleotide; and
f) collapsing sequence reads in each family to yield a base call for each family corresponding to one or more genetic loci.
US Pat. No. 10,693,031

MULTICRYSTALLINE SILICON INGOTS, SILICON MASTERALLOY, METHOD FOR INCREASING THE YIELD OF MULTICRYSTALLINE SILICON INGOTS FOR SOLAR CELLS

REC SOLAR NORWAY AS, Kri...

1. A method for minimizing or removing the red zone in directional solidified multicrystalline silicon ingots comprising adding calcium in its elemental form, or in the form of a silicon-calcium masteralloy comprising elemental calcium in an amount of 0.5-20 weight %, the remaining being high purity silicon, to a silicon melt in an amount chosen from one of the following ranges: 5-9.99 ppmw, 10-500 ppmw, 500-550 ppmw prior to subjecting the silicon melt to directional solidification in a crucible.
US Pat. No. 10,688,162

HYBRID NEUROTOXINS AND USES THEREOF

CELLSNAP LLC, Madison, W...

1. A hybrid botulinum neurotoxin (BoNT) toxin molecule comprising a light chain polypeptide from a first subtype and heavy chain polypeptide from a second subtype, wherein the hybrid is selected from the group consisting of A1/A2 A2/A1, A1/A3, A3/A1, A1/A4 and A4/A1.
US Pat. No. 10,689,443

HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON AND PANCREAS CANCER

PRECISION BIOLOGICS, INC....

1. A method of reducing the incidence of or treating a cancer that expresses the A33 antigen, comprising administering an effective amount of an antibody or fragment thereof that binds to said A33 antigen to a subject in need thereof, wherein said antibody or fragment thereof comprises:a) a heavy chain comprising the variable chain of antibody cdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:74) and a light chain comprising the variable light chain of antibody cdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:84);
b) a heavy chain comprising the variable chain of antibody cdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:74) and a light chain comprising the variable light chain of antibody abb31.1-LC (amino acids 1 to 107 of SEQ ID NO:85);
c) a heavy chain comprising the variable chain of antibody cdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:74) and a light chain comprising the variable light chain of antibody sdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:86);
d) a heavy chain comprising the variable chain of antibody cdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:74) and a light chain comprising the variable light chain of antibody ven31.1-LC (amino acids 1 to 107 of SEQ ID NO:87);
e) a heavy chain comprising the variable chain of antibody abb31.1-HC (amino acids 1 to 118 of SEQ ID NO:75) and a light chain comprising the variable light chain of antibody cdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:84);
f) a heavy chain comprising the variable chain of antibody abb31.1-HC (amino acids 1 to 118 of SEQ ID NO:75) and a light chain comprising the variable light chain of antibody abb31.1-LC (amino acids 1 to 107 of SEQ ID NO:85);
g) a heavy chain comprising the variable chain of antibody abb31.1-HC (amino acids 1 to 118 of SEQ ID NO:75) and a light chain comprising the variable light chain of antibody sdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:86);
h) a heavy chain comprising the variable chain of antibody abb31.1-HC (amino acids 1 to 118 of SEQ ID NO:75) and a light chain comprising the variable light chain of antibody ven31.1-LC (amino acids 1 to 107 of SEQ ID NO:87);
i) a heavy chain comprising the variable chain of antibody sdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:76) and a light chain comprising the variable light chain of antibody cdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:84);
j) a heavy chain comprising the variable chain of antibody sdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:76) and a light chain comprising the variable light chain of antibody abb31.1-LC (amino acids 1 to 107 of SEQ ID NO:85);
k) a heavy chain comprising the variable chain of antibody sdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:76) and a light chain comprising the variable light chain of antibody sdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:86);
l) a heavy chain comprising the variable chain of antibody sdr31.1-HC (amino acids 1 to 118 of SEQ ID NO:76) and a light chain comprising the variable light chain of antibody ven31.1-LC (amino acids 1 to 107 of SEQ ID NO:87);
m) a heavy chain comprising the variable chain of antibody ven31.1-HC (amino acids 1 to 118 of SEQ ID NO:77) and a light chain comprising the variable light chain of antibody cdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:84);
n) a heavy chain comprising the variable chain of antibody ven31.1-HC (amino acids 1 to 118 of SEQ ID NO:77) and a light chain comprising the variable light chain of antibody abb31.1-LC (amino acids 1 to 107 of SEQ ID NO:85);
o) a heavy chain comprising the variable chain of antibody ven31.1-HC (amino acids 1 to 118 of SEQ ID NO:77) and a light chain comprising the variable light chain of antibody sdr31.1-LC (amino acids 1 to 107 of SEQ ID NO:86);
p) a heavy chain comprising the variable chain of antibody ven31.1-HC (amino acids 1 to 118 of SEQ ID NO:77) and a light chain comprising the variable light chain of antibody ven31.1-LC (amino acids 1 to 107 of SEQ ID NO:87);
q) a heavy chain polypeptide of antibody cdr31.1-HC (SEQ ID NO:74) and a light chain polypeptide of antibody cdr31.1-LC (SEQ ID NO:84);
r) a heavy chain polypeptide of antibody cdr31.1-HC (SEQ ID NO:74) and a light chain polypeptide of antibody abb31.1-LC (SEQ ID NO:85);
s) a heavy chain polypeptide of antibody cdr31.1-HC (SEQ ID NO:74) and a light chain polypeptide of antibody sdr31.1-LC (SEQ ID NO:86);
t) a heavy chain polypeptide of antibody cdr31.1-HC (SEQ ID NO:74) and a light chain polypeptide of antibody ven31.1-LC (SEQ ID NO:87);
u) a heavy chain polypeptide of antibody abb31.1-HC (SEQ ID NO:75) and a light chain polypeptide of antibody cdr31.1-LC (SEQ ID NO:84);
v) a heavy chain polypeptide of antibody abb31.1-HC (SEQ ID NO:75) and a light chain polypeptide of antibody abb31.1-LC (SEQ ID NO:85);
w) a heavy chain polypeptide of antibody abb31.1-HC (SEQ ID NO:75) and a light chain polypeptide of antibody sdr31.1-LC (SEQ ID NO:86);
x) a heavy chain polypeptide of antibody abb31.1-HC (SEQ ID NO:75) and a light chain polypeptide of antibody ven31.1-LC (SEQ ID NO:87);
y) a heavy chain polypeptide of antibody sdr31.1-HC (SEQ ID NO:76) and a light chain polypeptide of antibody cdr31.1-LC (SEQ ID NO:84);
z) a heavy chain polypeptide of antibody sdr31.1-HC (SEQ ID NO:76) and a light chain polypeptide of antibody abb31.1-LC (SEQ ID NO:85);
aa) a heavy chain polypeptide of antibody sdr31.1-HC (SEQ ID NO:76) and a light chain polypeptide of antibody sdr31.1-LC (SEQ ID NO:86);
bb) a heavy chain polypeptide of antibody sdr31.1-HC (SEQ ID NO:76) and a light chain polypeptide of antibody ven31.1-LC (SEQ ID NO:87);
cc) a heavy chain polypeptide of antibody ven31.1-HC (SEQ ID NO:77) and a light chain polypeptide of antibody cdr31.1-LC (SEQ ID NO:84);
dd) a heavy chain polypeptide of antibody ven31.1-HC (SEQ ID NO:77) and a light chain polypeptide of antibody abb31.1-LC (SEQ ID NO:85);
ee) a heavy chain polypeptide of antibody ven31.1-HC (SEQ ID NO:77) and a light chain polypeptide of antibody sdr31.1-LC (SEQ ID NO:86); or
ff) a heavy chain polypeptide of antibody ven31.1-HC (SEQ ID NO:77) and a light chain polypeptide of antibody ven31.1-LC (SEQ ID NO:87).
US Pat. No. 10,689,700

METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING

UNIVERSITY OF WASHINGTON ...

1. A method for detecting genomic mutations in a biological source following an exposure to a DNA damaging agent, comprising:providing a sample from the biological source following the exposure, wherein the sample comprises a plurality of double-stranded DNA molecules;
attaching adapter molecules to individual double-stranded DNA molecules to generate a plurality of adapter-DNA molecules;
for each adapter-DNA molecule among at least a portion of the adapter-DNA molecules:
generating a set of copies of an original first strand of the adapter-DNA molecule and a set of distinct yet related copies of an original second strand of the adapter-DNA molecule;
sequencing one or more copies of the original first and second strands to provide a first strand sequence and a second strand sequence; and
aligning the first strand sequence, the second strand sequence or both the first and second strand sequences to a reference sequence to identify one or more reference correspondences; and
analyzing the one or more reference correspondences for each of the adapter-DNA molecules to determine at least one of a mutation spectrum, a mutation pattern, a mutation frequency, a mutation type, a DNA damage signature, a copy number variation and a genomic distribution of mutations in the sample.
US Pat. No. 10,688,163

TARGETED ANTIMICROBIALS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS

Lawrence Livermore Nation...

1. An antimicrobial composition comprising an effective amount of a targeted antimicrobial protein for Bacillus cereus or a microorganism related thereto,a suitable vehicle, and
one or more polyamines and/or polymixins,
wherein the targeted antimicrobial protein has a catalytic domain and a binding domain, the targeted antimicrobial protein being BCZK2532 protein having SEQ ID NO: 3 and/or a related lysin protein having lytic activity,
wherein the related lysin protein has at least a 40% percentage identity with the BCZK2532 protein having SEQ ID NO: 3 or a portion thereof, and
wherein the related lysin protein has an arginine in a position corresponding upon alignment to amino acid residue 100 of SEQ ID NO: 3.
US Pat. No. 10,689,444

RECOMBINANT MONOVALENT ANTIBODIES

OSE Immunotherapeutics, ...

1. A recombinant antibody derived from a parent antibody directed against an antigen of interest, wherein said recombinant antibody is an heterodimer of:i. a first protein chain consisting essentially of, from its N-terminus to its C-terminus:
a. a region A having the structure of the variable domain of the heavy chain of an immunoglobulin, said region A comprising the CDRs of the heavy chain of said parent antibody;
b. a region B consisting of a peptide linker and the CH2 and CH3 domains of an IgG immunoglobulin, wherein said peptide linker comprises one or more cysteine residues;
ii. a second protein chain consisting essentially of, from its N-terminus to its C-terminus:
a. a region A? having the structure of the variable domain of the light chain of an immunoglobulin, said region A? comprising the CDRs of the light chain of said parent antibody;
b. a region B identical to the region B of the first polypeptide;wherein said first and second protein chains are devoid of a hinge region or any portion thereof and of a CH1 domain of an IgG immunoglobulin, and the first and second protein chains are linked by at least one inter-chain disulfide bond.
US Pat. No. 10,689,701

BIOMARKERS FOR THE MOLECULAR CLASSIFICATION OF BACTERIAL INFECTION

Duke University, Durham,...

1. A method of developing a diagnostic assay for identifying and/or classifying a bacterial infection in a subject and treating the subject, the method comprising:(a) determining the gene expression levels of biomarkers in a blood sample from the subject using microarray analysis, or PCR, or a combination thereof, wherein the biomarkers comprise the biomarkers of Factor 20 and Factor 74 listed in Table 8 and Table 10, and wherein the gene expression levels in the subject are up-regulated or down-regulated more than 1-fold compared to a control population with known bacterial infection status, with a regression model based on weighted gene expression levels that provides a classification accuracy or an area under the curve (AUC) value of about 0.8100 to about 0.9999 compared to a probability of infection in the control population;
(b) identifying the subject as having a bacterial infection based on the gene expression levels in the subject determined in step (a); and
(c) administering an effective amount of antibiotic therapy to the subject identified as having a bacterial infection in step (b).
US Pat. No. 10,688,164

CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS

1. A method of generating an immune response to at least one heterologous antigen in a subject, the method comprising administering to the subject a cytomegalovirus (CMV) vector in an amount effective to elicit a CD8+ T cell response to the at least one heterologous antigen in the subject, wherein the CMV vector comprises:(a) a first nucleic acid sequence encoding at least one heterologous antigen;
(b) a second nucleic acid sequence comprising a first microRNA recognition element (MRE) operably linked to a CMV gene that is essential or augmenting for CMV growth and wherein the MRE silences expression in presence of miR-142-3p;
(c) a third nucleic acid sequence that encodes an active UL128 protein or ortholog thereof; and
(d) a fourth nucleic acid sequence that encodes an active UL130 protein or ortholog thereof.
US Pat. No. 10,689,445

ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF

Ventana Medical Systems, ...

1. An isolated antibody that specifically binds PD-L1, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) that comprises the following hypervariable regions (HVRs):(a) an HVR-H1 comprising the amino acid sequence of SNGLT (SEQ ID NO: 2);
(b) an HVR-H2 comprising the amino acid sequence of TINKDASAYYASWAKG (SEQ ID NO: 3);
(c) an HVR-H3 comprising the amino acid sequence of IAFKTGTSI (SEQ ID NO:4);
(d) an HVR-L1 comprising the amino acid sequence of QASESVYSNNYLS (SEQ ID NO: 9);
(e) an HVR-L2 comprising the amino acid sequence of LASTLAS (SEQ ID NO: 10); and
(f) an HVR-L3 comprising the amino acid sequence of IGGKSSSTDGNA (SEQ ID NO: 11).
US Pat. No. 10,689,702

BIOMARKERS FOR DIABETES

The Chinese University of...

1. A method for reducing risk of type 2 diabetes in a subject, comprising the steps of:(a) performing a polymerase chain reaction (PCR) to determine nucleotide sequence of at least a portion of genomic sequence of carboxypeptidase E (CPE) present in a biological sample taken from the subject,
(b) detecting a G allele in polymorphism rs1583645,
(c) determining the subject as having an increased risk of developing type 2 diabetes based on a G allele being detected in polymorphism rs1583645, and
(d) administering to the subject who is determined in step (c) as having an increased risk of developing type 2 diabetes a medicine to reduce risk of onset of diabetes.
US Pat. No. 10,692,522

MAGNETIC RECORDING MEDIUM HAVING CHARACTERIZED MAGNETIC LAYER AND METHOD FOR MANUFACTURING SAME

FUJIFILM Corporation, To...

1. A magnetic recording medium comprising:a non-magnetic support; and
a magnetic layer which is provided on the support and contains ferromagnetic powder and a binder,
wherein the ferromagnetic powder is ferromagnetic hexagonal ferrite powder,
the magnetic layer contains an abrasive,
an intensity ratio (Int (110)/Int (114)) of a peak intensity Int (110) of a diffraction peak of (110) plane of a crystal structure of the hexagonal ferrite, determined by performing X-ray diffraction analysis on the magnetic layer by using an In-Plane method, to a peak intensity Int (114) of a diffraction peak of (114) plane of the crystal structure is equal to or higher than 0.5 and equal to or lower than 4.0, and
a squareness ratio in a vertical direction is equal to or higher than 0.65 and equal to or lower than 1.00.
US Pat. No. 10,688,165

MEDICAMENT FOR USE IN A METHOD OF INDUCING OR EXTENDING A CELLULAR CYTOTOXIC IMMUNE RESPONSE

1. A method of inducing and amplifying antigen-specific CD8+ T cells in a patient, the method comprising the steps of (A) and (B), wherein step (A) is selected from (A)(i), (A)(ii), or (A)(iii), and step (A) is followed by step (B):(A) (i)
(1) administering to said patient a delivery system comprising:
(a) a molecule that binds to a receptor on the surface of an antigen-presenting cell, and
(b) an antigen-comprising protein bound to the molecule of (a) and wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the antigen-presenting cell and the antigen comprised in the protein is presented on the surface of the antigen-presenting cell, thereby activating CD8+ T cells in the patient, and
(2) administering a further adjuvant which supports a Th-1-mediated response, or
(ii)
(1) activating one or more CD8+ T cells obtained from said patient in vitro with an antigen-comprising protein or a fragment thereof comprising the antigen,
(2) re-transferring one or more CD8+ T cells obtained in step (1) to said patient, and
(3) optionally administering a further adjuvant which supports a Th-1-mediated response,
or
(iii)
(1) administering to said patient an antigen-comprising protein or a fragment thereof comprising the antigen,
or
a nucleic acid comprising a nucleic acid sequence encoding an antigen-comprising protein or a fragment thereof comprising the antigen, which is capable of expressing the antigen-comprising protein or a fragment thereof comprising the antigen in said patient,
thereby activating CD8+ T cells,
and
(2) administering a further adjuvant which supports a Th-1-mediated response, and
(B) administering to the patient a reactivator comprising:
(1) primary peptide-loaded major histocompatibility complex class I (MHC I) presenting cells, wherein the MHC I presenting cells do not comprise monocyte-derived dendritic cells, and wherein the peptide is derived from the antigen-comprising protein of step (A), and
(2) an adjuvant which supports a Th-1-mediated response,
thereby re-activating the activated CD8+ T cells of step (A), and wherein the reactivator
is administered in a time frame of from 5 to 12 days after the CD8+ T cells were activated against the antigen in step (A), and
is administered only once to said patient during the time frame, and
is administered intravenously to said patient, and
wherein the MHC I presenting cells are obtained from said patient and peptide-loaded in vitro between 2 h and 3 days prior to administration to the patient.
US Pat. No. 10,689,446

RECOMBINANT CD74 POLYPEPTIDES

THE UNITED STATES GOVERNM...

1. A recombinant polypeptide comprising: the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3.
US Pat. No. 10,689,703

METHODS OF IDENTIFYING AND TREATING SUBJECTS HAVING ACUTE RESPIRATORY DISTRESS SYNDROME

National Jewish Health, ...

1. A method of treating a severe form of Acute Respiratory Distress Syndrome (ARDS) in a subject having been diagnosed as having ARDS comprising:a. extracting RNA from neutrophils obtained from the subject;
b. quantifying relative RNA expression levels of each of myxovirus resistance 1 (MXI), interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), and interferon-stimulated 15 kDa protein (ISG15) in the extracted RNA by quantitative PCR;
c. comparing the RNA expression levels from step b against control RNA expression levels of MX1, IFIT1, and ISG15, wherein the control RNA expression levels are the mean RNA expression levels of the same genes predetermined from a reference level known to correlate with a severe form of ARDS, wherein RNA expression levels from the subject is less than one standard deviation above the mean as compared to the control RNA expression levels identifies the subject has having a severe form of ARDS; and
d. treating the subject identified in step c comprising administering to the subject a therapeutic effective amount of an ISG enhancing agent selected from the group consisting of interferon-alpha, interferon-beta and type III interferon.
US Pat. No. 10,688,166

COMPOSITIONS AND METHODS FOR IMPROVED CAR-T CELL THERAPIES

CERUS CORPORATION, Conco...

1. A CAR-T cell-derived effector cell population comprising:a population of activated T cells expressing a chimeric antigen receptor (CAR), the CAR comprising an extracellular domain which specifically binds a predetermined antigen, a transmembrane domain, and a cytoplasmic co-stimulatory signaling domain, wherein the nucleic acid of the activated T cells have been modified by reaction with a nucleic acid targeting compound that reacts directly with the nucleic acid so that the activated T cells are attenuated for proliferation, wherein the activated T cells are present in the population in a therapeutically effective amount for treatment of a malignancy that expresses the predetermined antigen.
US Pat. No. 10,689,447

FC VARIANTS AND METHODS FOR THEIR PRODUCTION

Genentech, Inc., South S...

1. A heteromultimeric protein or an IgG antibody, wherein the heteromultimeric protein or the IgG antibody each comprises an Fc region comprising substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243 S and (b) F241S and F243R, wherein numbering is according to the EU numbering scheme, wherein no amino acid residue of any Fc polypeptide of the heteromultimeric protein or the IgG antibody is glycosylated, and wherein said heteromultimeric protein or IgG antibody exhibits decreased mispairing, decreased head-to-tail formation or increased overall yield as compared to a heteromultimeric protein or an IgG antibody without said amino acid substitution mutations at residues 241 and 243.
US Pat. No. 10,693,036

METHOD FOR MANUFACTURING TUNNEL JUNCTION LAYER

SHOWA DENKO K. K., Tokyo...

1. A method for manufacturing a tunnel junction layer using organic vapor phase deposition, the method comprising:a first process that supplies a first material gas containing a group III element, a second material gas containing a group V element, and a third material gas containing a dopant of a first conductivity type, onto a compound semiconductor layer on which the tunnel junction layer is to be laminated;
a second process that stops supplying the first material gas, the second material gas and the third material gas, and supplies a fourth material gas containing a dopant of a second conductivity type opposite to the first conductivity type; and
a third process that continues to supply the fourth material gas, and further supplies a fifth material gas containing a group III element and a sixth material gas containing a group V element.
US Pat. No. 10,688,167

METHODS AND COMPOSITIONS FOR REDUCING GROWTH, MIGRATION AND INVASIVENESS OF BRAIN CANCER STEM CELLS AND IMPROVING SURVIVAL OF PATIENTS WITH BRAIN TUMORS

HYPERSTEM SA, Lugano (CH...

1. A pharmaceutical composition comprising a therapeutic amount of a therapeutic agent and a pharmaceutically acceptable carrier, wherein the therapeutic agent is a t-butyloxycarbonyl peptide derivative of Wnt5a, selected from Peptide A (SEQ ID NO: 2), Peptide B (SEQ ID NO: 3), for a combination of Peptide A (SEQ ID NO: 2) and Peptide B (SEQ ID NO: 3), and wherein the t-butyloxicarbonyl peptide derivative of Wnt5a is formulated per se or in salt form.
US Pat. No. 10,689,448

MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

GALAXY BIOTECH, LLC, Cup...

1. A pharmaceutical composition comprising a monoclonal antibody (mAb) that binds human fibroblast growth factor receptor 2 isoform IIIb (FGFR2IIIb) comprising a light chain variable region comprising complementarity determining region (CDR)1, CDR2, and CDR3 respectively defined by residues 24-34, 50-56, and 89-97 of SEQ ID NO:1, and comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 31-35, 50-66 and 99-103 of SEQ ID NO:4, and a pharmaceutically acceptable carrier.
US Pat. No. 10,689,705

FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME

Chugai Seiyaku Kabushiki ...

1. A method of treating a subject who has cancer, the method comprising(a) determining that a sample comprising tumor cells from the subject comprises:
(i) a fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide consists of the amino acid sequence of SEQ ID NO: 32; or
(ii) a polynucleotide encoding the fusion polypeptide, and
(b) administering to the subject an FGFR3 inhibitor in an amount effective to inhibit tumor growth in the subject.
US Pat. No. 10,688,168

METHODS FOR INDUCING AN IMMUNE RESPONSE

GlaxoSmithKline Biologica...

1. A method for inducing an immune response in a subject comprising:(i) administration of a dose of a first immunogenic composition comprising a polypeptide sequence having at least 90% identity to SEQ ID NO:1 and a first adjuvant, wherein the first adjuvant comprises a TLR agonist, an immunologically active saponin, or both to the subject; followed by
(ii) administration of a dose of a second immunogenic composition comprising a polypeptide sequence having at least 90% identity to SEQ ID NO:1 to the subject;
and wherein the subject receives a total of three doses of immunogenic compositions within a five year period; wherein the subject receives two doses of the first immunogenic composition and one dose of the second immunogenic composition, where the time interval between the final administration of the first composition and administration of the second composition is between 3 months and 5 years.
US Pat. No. 10,689,449

MULTIMERIC DEATH DOMAIN-CONTAINING RECEPTOR-5 (DR5) ANTIBODIES AND USES THEREOF

IGM Biosciences, Inc., M...

1. An antibody comprising two, five, or six bivalent binding units or variants or fragments thereof,wherein each binding unit comprises two IgA or IgM heavy chain constant regions or fragments thereof, each associated with an antibody antigen-binding domain,
wherein at least three of the antigen-binding domains of the antibody specifically and agonistically bind to the tumor necrosis factor (TNF) superfamily receptor protein death domain-containing receptor-5 (DR5) and can induce apoptosis of a cell expressing DR5, and
wherein the antibody can cross-link at least three DR5 proteins expressed on the surface of a cell, thereby inducing apoptosis of the cell.
US Pat. No. 10,689,706

METHYLATION PATTERN ANALYSIS OF HAPLOTYPES IN TISSUES IN A DNA MIXTURE

The Chinese University of...

1. A method of determining a portion of a fetal genome of an unborn fetus of a pregnant female using a biological sample from the pregnant female, wherein the biological sample including a mixture of cell-free DNA molecules from a plurality of tissues types, including maternal tissue types and a fetal tissue type, the unborn fetus having a father and a mother being the pregnant female, the method comprising:analyzing, by a computer system, a plurality of cell-free DNA molecules from the biological sample, the plurality of cell-free DNA molecules being at least 1,000 cell-free DNA molecules, wherein analyzing a cell-free DNA molecule includes:
identifying a location of the cell-free DNA molecule in a reference human genome; and
determining a respective allele of the cell-free DNA molecule;
determining a first haplotype and a second haplotype of a first chromosomal region of a first parental genome of a first parent of the unborn fetus;
identifying one or more heterozygous loci of the first chromosomal region of the first parental genome, each heterozygous locus including a corresponding first allele in the first haplotype and a corresponding second allele in the second haplotype;
identifying a first set of the plurality of cell-free DNA molecules that each:
is located at any one of the one or more heterozygous loci,
includes the corresponding first allele of the heterozygous locus, and
includes at least one of N genomic sites, N being an integer greater than or equal to 2;
measuring N first mixture methylation levels at the N genomic sites using the first set of the plurality of cell-free DNA molecules;
determining, by the computer system, a first fractional contribution of the fetal tissue type in the mixture using the N first mixture methylation levels;
identifying a second set of the plurality of cell-free DNA molecules that each:
is located at any one of the one or more heterozygous loci,
includes the corresponding second allele, and
includes at least one of the N genomic sites;
measuring N second mixture methylation levels at the N genomic sites using the second set of the plurality of cell-free DNA molecules;
determining, by the computer system, a second fractional contribution of the fetal tissue type in the mixture using the N second mixture methylation levels;
computing a first separation value between the first fractional contribution and the second fractional contribution; and
determining the portion of the fetal genome at the one or more heterozygous loci based on the first separation value.
US Pat. No. 10,689,450

BCMA BINDING MOLECULES AND METHODS OF USE THEREOF

KITE PHARMA, INC, Santa ...

1. An isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising an antigen binding molecule that specifically binds to B-cell maturation antigen (BCMA), wherein the antigen binding molecule comprises:(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113;
(b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114;
(c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 43; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115;
(d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 28; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 44; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116;
(e) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 13; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 45; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117;
(f) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 14; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 46; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118;
(g) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119; or
(h) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 16; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 32; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120.
US Pat. No. 10,689,707

TREATMENT OF RECURRENT GASTRIC CANCER IDENTIFIED USING GENETIC BIOMARKERS

Pacific Edge Limited, Du...

1. A method for detecting specific cancer markers to determine the efficacy of surgical, radiotherapeutic, and/or chemotherapeutic treatments in a patient having gastric cancer and treating said patient, comprising:(a) providing a sample containing one or more nucleic acids;
(b) detecting, using quantitative polymerase chain reaction (qPCR) expression of cystatin SN (CST-1,2,4), inhibin beta A (INHBA), asporin (ASPN), and secreted frizzled-related protein 4 (“SFRP4”), wherein CST1-1,2,4 is detected using a forward primer having the sequence of SEQ ID NO. 3, and wherein ASPN is detected using a forward primer having the sequence of SEQ ID NO.1;
c) calculating the ratios of expression of said CST-1,2,4, INHBA, ASPN, and SFRP4 in said tissue sample compared to expression of said CST-1,2,4, INHBA, ASPN, and SFRP4 from non-tumor tissue, by calculating the ?CT (target gene CT—mean reference cDNA CT), where ?CT is directly proportional to the negative log2 fold change, relative to the median non-malignant log2 fold change, where the median ratios of expression in said tissue sample to the level of expression in said non-tumor tissue are greater than 525, 34, 12, and 56, respectively, thereby indicating the presence of gastric cancer after treatment; and
(d) treating the patient with surgery, radiotherapy, or chemotherapy.
US Pat. No. 10,688,170

MULTIVALENT CONJUGATE VACCINES WITH BIVALENT OR MULTIVALENT CONJUGATE POLYSACCHARIDES THAT PROVIDE IMPROVED IMMUNOGENICITY AND AVIDITY

Inventprise, LLC, Redmon...

1. An immunogenic composition comprising:first and second group conjugates, wherein:
first group conjugates comprise a first collection of monovalent conjugates, wherein each monovalent conjugate comprises a first carrier protein and a capsular polysaccharide of Streptococcus pneumoniae and the first collection includes capsular polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B; and
second group conjugates comprise a second collection of bivalent and/or multivalent conjugates, wherein each bivalent or multivalent conjugate comprises a second carrier protein and at least two capsular polysaccharides of Streptococcus pneumoniae, selected from one or more of the groups consisting Streptococcus pneumoniae serotypes 6A, 6B, 6C, and and/or 6D, Streptococcus pneumoniae serotypes 9V, 9N, 9A and 9B, Streptococcus pneumoniae serotypes 15B, 15A, and 15C, and Streptococcus pneumoniae serotypes 19A and 19F, wherein one or more of the capsular polysaccharides are coupled via a bifunctional linker, wherein the multivalent conjugate contains a quantity of carrier protein that is less than a quantity of capsular polysaccharide.
US Pat. No. 10,689,451

ANTI-BAFFR ANTIBODY THERAPEUTIC FORMULATIONS

Novartis AG, Basel (CH)

1. A ready for use aqueous pharmaceutical composition having a pH of about 5.5-about 6.5, comprising(i) about 18 mg/mL 165 mg/mL of a hypofucosylated or non-fucosylated anti-B-cell Activating Factor Receptor (BAFFR) antibody, wherein said anti-BAFFR antibody comprises heavy chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NOs: 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 amino acid sequences of SEQ ID NOs: 6, 7 and 8,
(ii) about 110 mM-250 mM sucrose or trehalose,
(iii) about 15 mM-25 mM histidine, citrate, or succinate,
(iv) up to about 0.02%-0.06% polysorbate 20, about 0.02%-0.06% poloxamer 188, or about 2.5 mM hydroxyproyl-b-cyclodextrin, and, optionally,
(v) about 2 mM-80 mM arginine.
US Pat. No. 10,689,708

METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR OF RESPONSIVENESS TO DRUGS

CELGENE CORPORATION, Sum...

1. A method for treating a human diffuse large B-cell lymphoma (DLBCL) patient comprising:(a) obtaining a first biological sample from a lymph-node biopsy of a human DLBCL patient;
(b) determining the nucleic acid expression levels of
(i) all genes from the group consisting of C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CILP, CIRH1A, CLU, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, LRP11, MEGF6, MEIS1, PHACTR2, PLAT, SERPING1, SPC25, THEMIS2, TPSAB1, ULK1, XAF1, and ZNF215;
(ii) all genes from the group consisting of ANXA4, BACH2, BIN2, C7orf10, CXCL14, DAPL1, FBXO32, FCGR1B, FTX, GIMAP6, IL18BP, KCNMB1, KIAA1671, LOC284837, MPP6, MZT1, NFIC, ODF3B, OLFM1, PPAT, RFESD, RPL22L1, SERPING1, TNC, TNFRSF17, and ZNF506; or
(iii) all genes from the group consisting of BMS1P20, MZB1, TNFRSF17, FKBP11, IGLV1-44, MS4A1, BCL11A, MACROD2, FAM129C, ALDH2, KIAA1598, TGFBI, TYMP, SAMD4A, GPX3, A2M, CFB, FSTL1, SLC27A3, and NRP1;
(c) classifying the patient as a responsive patient to the treatment of a drug using the nucleic acid expression levels determined in step (b) as compared to nucleic acid expression levels of the same genes in DLBCL patients whose responsiveness to the drug is known;
wherein the drug is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide); 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A); or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof;
(d) administering the drug to the responsive patient to the treatment of the drug as classified in step (c).
US Pat. No. 10,688,171

CHLAMYDIA-ACTIVATED B CELL PLATFORMS AND METHODS THEREOF

Ohio State Innovation Fou...

1. An ex vivo or in vitro platform for creating a cellular vaccine comprising activated, antigen-presenting cells (APCs) against an antigen of interest, wherein the platform comprises:a. a whole, inactivated Chlamydia spp. bacterium;
b. a population of B cells; and
c. the antigen of interest, wherein the antigen is not derived from a Chlamydia spp.;
wherein the population of B cells are exposed to the whole, inactivated Chlamydia spp. bacterium, thereby forming Chlamydia-activated B cells (CABs); wherein said CABs are then exposed or crosslinked to the antigen of interest, thereby forming a cellular vaccine comprising APCs.
US Pat. No. 10,689,452

MONOVALENT ANTI-HUTNFR1 ANTIBODIES, ENCODING NUCLEIC ACIDS THEREOF AND METHODS OF TREATMENT THEREOF

BALIOPHARM AG, Basel (CH...

1. An inhibitor of the human tumor necrosis factor receptor 1 (huTNFR1) receptor which is a human or humanized antibody construct that monovalently recognizes huTNFR1 through an antigen-binding moiety, wherein the antigen-binding moiety comprisesa heavy chain variable (VH) domain that comprises the complementarity-determining regions (CDR) sequences CDRH1, CDRH2, and CDRH3, and
a light chain variable (VL) domain that comprises the CDR sequences CDRL1, CDRL2, and CDRL3, wherein:
a) the CDRH1 sequence is identified as SEQ ID NO: 1;
b) the CDRH2 sequence is identified as SEQ ID NO: 10;
c) the CDRH3 sequence is identified as SEQ ID NO: 3;
d) the CDRL1 sequence is identified as SEQ ID NO: 4;
e) the CDRL2 sequence is identified as SEQ ID NO: 5; and
f) the CDRL3 sequence is identified as SEQ ID NO: 11.
US Pat. No. 10,689,709

KIT AND METHOD FOR DETECTING MUTATIONS IN CTNNB1 AND HTERT, AND USE THEREOF IN HCC DETECTION AND DISEASE MANAGEMENT

JBS Science Inc., Doyles...

1. A kit for characterizing, in a biological sample containing at least one first allele of a gene, at least one second allele in a genomic region of the gene, the kit comprising:a first pair of primers, configured to specifically bind sequences flanking the genomic region to thereby allow amplification of at least one polynucleotide harboring the genomic region in a first PCR reaction; and
at least one clamp, each configured to bind to one of the at least one first allele but not any of the at least one second allele at an annealing temperature in the first PCR reaction to thereby selectively suppress amplification of the one of the at least one first allele but still allow amplification of the at least one second allele:
wherein:
the gene is hTERT, the genomic region comprises nucleotide position ?129 to ?119 upstream from a start codon of hTERT, the at least one first allele comprises a wildtype allele of hTERT, the at least one second allele comprises one or more mutant alleles of hTERT in the genomic region, and the at least one clamp comprises a bridged nucleic acid (BNA) clamp specifically targeting the wildtype allele of hTERT;
at least one of the first pair of primers comprises an oligonucleotide of an artificial sequence at a 5?-end thereof, configured to interrupt a secondary structure of DNA molecules of the gene or to increase a Tm of the at least one of the first pair of primers in the first PCR reaction using amplified products as templates to thereby increase an efficiency of the amplification of the at least one polynucleotide in the first PCR reaction; and
the first pair of primers respectively have nucleotide sequences comprising SEQ ID NO: 11 and SEQ ID NO: 12.
US Pat. No. 10,688,172

HPV PARTICLES AND USES THEREOF

Aura Biosciences, Inc., ...

1. A method comprising:expressing in a host cell nucleic acids encoding modified papillomavirus L1 proteins that comprise an FG loop corresponding to the amino acid sequence of SEQ ID NO: 66; and
isolating nanoparticles self-assembled from the papillomavirus L1 proteins.
US Pat. No. 10,689,453

METHODS OF INHIBITING NAIVE T-CELL PROLIFERATION USING ANTI-CD27 ANTIBODIES

Janssen Biotech, Inc., H...

1. A method of inhibiting naïve T-cell proliferation, comprising contacting a portion of human T-cells with an effective amount of a human CD27 antibody or antigen-binding fragment thereof comprising a light chain variable region and a heavy chain variable region, said light chain variable region comprising:a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOs: 59-66 and 158;
a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOs: 67-74; and
a CDRL3 amino acid sequence of SEQ ID NO: 75;
said heavy chain variable region comprising:
a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs: 42-45 and 161;
a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOs: 46-57, 156, and 157; and
a CDRH3 amino acid sequence of SEQ ID NO: 58, and the antibody or antigen binding portion thereof inhibits the activation of CD27 on said human T-cells in the presence of human CD70 protein.
US Pat. No. 10,689,710

METHODS FOR SCREENING SOLID TUMORS FOR MUTATIONS

Quest Diagnostics Investm...

1. A method for detecting at least one mutation in a plurality of cancer-related genes in a subject comprising(a) extracting genomic DNA from a formalin fixed paraffin-embedded tumor sample obtained from the subject;
(b) generating a library comprising amplicons corresponding to each of the plurality of cancer-related genes, said plurality of cancer-related genes comprising AKT1, ERBB2, FOXL2, IDH2, NRAS, RET, ALK, ERBB4, GNA11, KIT, PDGFRA, SMO, BRAF, FBXW7, GNAQ, KRAS, PIK3CA, STKl1, CTNNB1, FGFR2, GNAS, MAP2K1, PIK3R1, TP53, DDR2, FGFR3, HRAS, MET, PTCH1, EGFR, FGFR4, IDH1, NOTCH1, and PTEN, wherein the amplicons are generated in a multiplex amplification reaction using primer pairs specific for each of the cancer-related genes and wherein at least two of the primer pairs are selected from the group consisting of the primers of SEQ ID NOS: 1-18, 45-54, and 71-274 or the group consisting of the primers of SEQ ID NOS: 19-44, 55-70, and 275-464, wherein:
(i) generating said library proceeds independently of using a bait set comprising nucleic acid sequences that are complementary to at least one of the plurality of amplicons; and
(ii) the quality of the genomic DNA extracted from the formalin fixed paraffin-embedded tumor sample is not assessed using quantitative PCR prior to generating the library;
(c) ligating an adapter sequence to the ends of the plurality of amplicons; and
(d) detecting at least one mutation in at least one of the plurality of amplicons using high throughput massive parallel sequencing.
US Pat. No. 10,688,173

HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES

ACADEMISCH ZIEKENHUIS LEI...

1. An immunogenic pharmaceutical composition comprising:(a) a peptide having a length of no more than 45 amino acids and comprising at least 31 and no more than 35 contiguous amino acids from the amino acid sequence of an HPV E7 protein, wherein the contiguous amino acid sequence comprises SEQ ID NO:17; and
(b) an immune-stimulating amount of a pharmaceutically acceptable adjuvant.
US Pat. No. 10,689,454

ANTI-CD137 ANTIBODIES AND USES THEREOF

ALLIGATOR BIOSCIENCE AB, ...

1. An antibody or an antigen-binding fragment thereof with binding specificity for domain 2 of human CD137 wherein the antibody or antigen-binding fragment is a CD137 agonist and comprises a heavy chain variable region and a light chain variable region comprising the amino acid sequences of SEQ ID NO: 19 and SEQ ID NO: 20.
US Pat. No. 10,689,711

TEST KITS AND METHODS FOR THEIR USE TO DETECT GENETIC MARKERS FOR UROTHELIAL CARCINOMA OF THE BLADDER AND TREATMENT THEREOF

PACIFIC EDGE LIMITED, Du...

16. A method for treating urothelial carcinoma by detecting genetic markers for transitional cell carcinoma also known as urothelial carcinoma of the bladder, comprising:a) obtaining a sample of urine from a subject;
b) using RT-PCR to detect the expression level as the threshold cycle (?Ct) of insulin-like growth factor binding protein 5 (IGFBP5), homeobox A13 (HOXA13), midkine (MDK), and leukotriene B4 12-dehydrogenase (LTB4DH) in said sample;
c) calculating the ratios of expression levels in said sample of at least one of IGFBP5/LTB4DH, HOXA13/LTB4DH, and MDK/LTB4DH; and
d) using RT-PCR to detect the expression level as the calculating the ratios of expression levels in said sample of at least one of IGFBP5/LTB4DH, HOXA13/LTB4DH, and MDK/LTB4DH in samples from a group of patients not having urothelial carcinoma;
e) calculating the ratios of expression levels in said samples in step d) of at least one of IGFBP5/LTB4DH, HOXA13/LTB4DH, and MDK/LTB4DH;
f) detecting a ratio of expression levels of at least one of IGFBP5/LTB4DH, HOXA13/LTB4DH, and MDK/LTB4DH in step c) that is less than the ratio in step e),
g) diagnosing the subject as having urothelial carcinoma; and
h) treating patient diagnosed as having urothelial carcinoma using surgery, radiation therapy or chemotherapy as appropriate to the type and stage of the urothelial carcinoma.
US Pat. No. 10,688,174

METHOD OF CONFERRING A PROTECTIVE IMMUNE RESPONSE TO NOROVIRUS

Takeda Vaccines, Inc., C...

1. A method of eliciting protective immunity to a Norovirus infection in a human comprising administering to the human a vaccine comprising at least two Norovirus virus-like particles (VLPs), wherein the at least two VLPs represent different Norovirus genotypes, wherein at least one Norovirus VLP is present in the vaccine in a dose amount of from about 1 ug to about 200 ug, and wherein the vaccine is able to elicit immunity against each Norovirus genotype represented in the vaccine.
US Pat. No. 10,689,455

ANTI-JAGGED ANTIBODIES AND METHODS OF USE

Genentech, Inc., South S...

1. An isolated antibody that binds to Jagged2, wherein the antibody comprises:(i)
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:90;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:117;
(ii)
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:91;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:118;
(iii)
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:90;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:119;
or
(iv)
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:93;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:121.
US Pat. No. 10,689,712

COMPOSITIONS AND METHODS FOR DETECTING NUCLEIC ACID FROM MOLLICUTES

GEN-PROBE INCORPORATED, ...

1. A method for the in vitro amplification of a nucleic acid in a sample, the nucleic acid being from one or more species in the class Mollicutes, comprising the steps of:(a) contacting a sample with at least two tagged amplification oligomers, each of which individually comprises a target hybridizing region and a tag region, wherein the at least two tagged amplification oligomers are selected from the group consisting of:
(i) a tagged amplification oligomer comprising a target hybridizing region that is from 15 to 50 nucleobases in length and contains a nucleotide sequence that is configured to specifically hybridize to all or a portion of a region of a target nucleic acid corresponding to residues 5065 to 5088 of SEQ ID NO:1;
(ii) a tagged amplification oligomer comprising a target hybridizing region that is from 15 to 50 nucleobases in length and contains a nucleotide sequence that is configured to specifically hybridize to all or a portion of a region of a target nucleic acid corresponding to residues 4752 to 4798 of SEQ ID NO:2;
(iii) a tagged amplification oligomer comprising a target hybridizing region that is from 15 to 50 nucleobases in length and contains a nucleotide sequence that is configured to specifically hybridize to all or a portion of a region of a target nucleic acid corresponding to residues 1954 to 2006 of SEQ ID NO:3; and
(iv) a tagged amplification oligomer comprising a target hybridizing region that is from 15 to 50 nucleobases in length and contains a nucleotide sequence that is configured to specifically hybridize to all or a portion of a region of a target nucleic acid corresponding to residues 1994 to 2036 of SEQ ID NO:4;
wherein the tag region of each tagged amplification oligomer has the same nucleotide sequence; and
(b) providing suitable conditions for performing an in vitro amplification reaction.
US Pat. No. 10,688,175

NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONS

1. A fusion protein comprising a self-assembling coronavirus NSP10 protein and a protein or peptide capable of being fused to NSP10 without interfering with the assembly or aggregation of the resulting fusion protein, wherein the fusion protein forms a capsid assembly, and wherein the capsid is a dodecameric capsid exhibiting 32 point symmetry.
US Pat. No. 10,689,456

ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS

The United States of Amer...

1. A chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising:a CD70 binding—transmembrane domain comprising the amino acid sequence of SEQ ID NO: 3, wherein the CD70 binding—transmembrane domain does not comprise residues 212 to 260 of the amino acid sequence of SEQ ID NO: 2;
a CD3? intracellular T cell signaling domain comprising the amino acid sequence of SEQ ID NO: 4; and
one or both of (i) a 4-1BB intracellular T cell signaling domain comprising the amino acid sequence of SEQ ID NO: 5 and (ii) a CD28 intracellular T cell signaling domain comprising the amino acid sequence of SEQ ID NO: 6.
US Pat. No. 10,689,713

RED BLOOD CELL LYSIS SOLUTION

GEN-PROBE INCORPORATED, ...

1. A reagent comprising ammonium chloride at a concentration of 200-300 mM and lithium lauryl sulfate (LLS) at a concentration of 4% to 15% (w/v).
US Pat. No. 10,688,176

REOVIRIDAE VACCINE

1. An isolated viral ssRNA comprising at least a part of an S9 segment from an African Horse Sickness Virus (AHSV) genome, wherein the at least a part of the S9 segment comprises a plurality of mutations, each mutation providing or encoding a stop codon that destroys a function of at least one essential gene while retaining a length of the S9 segment.
US Pat. No. 10,689,457

TREATMENT OF METASTATIC BREAST CANCER

GENENTECH, INC., South S...

1. A method for the treatment of a human patient with HER2 positive metastatic breast cancer who did not receive either prior chemotherapy or prior anti-HER2 therapy for their metastatic breast cancer, comprising administering to the patient an effective amount of a combination of pertuzumab, trastuzumab, and docetaxel, wherein treatment with the combination increases overall survival without increase in cardiac-specific adverse events relative to administration of trastuzumab and docetaxel in the absence of pertuzumab, wherein the pertuzumab is administered by intravenous infusion, at a fixed loading dose of 840 mg, followed by administration of a fixed dose of 420 mg every three weeks, the trastuzumab is administered by intravenous infusion at a loading dose of 8 mg/kg, followed by administration of a dose of 6 mg/kg every three weeks, and the docetaxel is administered by intravenous administration every three weeks for at least six cycles, wherein the initial dose of docetaxel is 75 mg/m2 and is increased to 100 mg/m2 if the patient tolerates the initial dose.
US Pat. No. 10,689,714

METHODS FOR IDENTIFYING POLYMORPHISMS LINKED TO THE PPO11 GENE

Seminis Vegetable Seeds, ...

1. A method of identifying a lettuce plant that displays reduced browning or increased shelf life comprising:a) obtaining a sample of nucleic acids from a population of lettuce plants or parts thereof, wherein members of the population vary for expression of a PPO11 gene having at least 95% sequence identity to SEQ ID NO:9;
b) detecting in said nucleic acids at least one polymorphism that is genetically linked to reduced expression of said PPO11 gene relative to members of the population that do not comprise said polymorphism;
c) crossing a lettuce plant comprising said polymorphism with a second lettuce plant;
d) obtaining seeds from said cross; and
e) growing at least one lettuce plant from said seeds, wherein said lettuce plant grown from said seeds comprises said polymorphism, has a reduced expression of PPO11, and has reduced browning or increased shelf life, when compared with a lettuce plant of the same variety that does not comprise said polymorphism.
US Pat. No. 10,688,177

NATURALLY-OCCURRING CPG OLIGONUCLEOTIDE COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF

1. A composition comprising:(a) a lysate and/or cell wall extract from a Gram-positive bacteria, or a pharmaceutically acceptable salt thereof; and
(b) an immunostimulatory oligodeoxynucleotide (ODN);
wherein the composition is formulated for oral delivery; and
wherein the composition is formulated to dissolve in not less than 1 minute after administration.
US Pat. No. 10,689,458

SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES

Pfizer Inc., New York, N...

1. An antibody drug conjugate of the formula: Ab-(L-D),wherein:(a) Ab is an antibody that binds to HER2 and comprises a heavy chain comprising SEQ ID NO:18 and a light chain comprising SEQ ID NO:42; and
(b) L-D is a linker-drug moiety, wherein L is maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (vc) and D is 2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide or a pharmaceutically acceptable salt or solvate thereof.
US Pat. No. 10,689,715

COMPOSITIONS AND METHODS FOR USE IN A PCR ASSAY FOR DETERMINING THE GENOTYPE AND VIRAL LOAD FOR RESPIRATORY SYNCYTIAL VIRUS

Laboratory Corporation of...

1. A method for simultaneously determining the viral load and genotype of a respiratory syncytial virus (RSV) in a biological sample, comprising:a) amplifying a nucleic acid sequence encoding an RSV open reading frame (ORF) in a biological sample using a single set of primers that specifically amplifies an RSV A ORF and an RSV B ORF, wherein said single set of primers is a single primer pair and at least two nucleic acid probes in a quantitative polymerase chain reaction (PCR) assay, wherein at least one probe specifically binds to an RSV subtype A nucleic acid sequence and at least one probe specifically binds to an RSV subtype B nucleic acid sequence, and wherein the at least two nucleic acid probes are differentially labeled; and
b) determining the viral load based on the amount of the amplified nucleic acid sequence produced by the quantitative PCR assay and determining the RSV subtype(s) present in the biological sample.
US Pat. No. 10,688,178

ANTIPLEXIN A1 AGONIST ANTIBODY

Osaka University, Osaka ...

1. An anti-Plexin-A1 agonist antibody selected from the group:(a) an isolated antibody that binds to Plexin-A1 comprising heavy chain variable region CDRs of SEQ ID NOS: 23, 24 and 25 and light chain variable regions CDRs of SEQ ID NOS: 26, 27 and 28,
(b) an isolated antibody that binds to Plexin-A1 comprising heavy chain variable region CDRs of SEQ ID NOS: 29, 30 and 31 and light chain variable regions CDRs of SEQ ID NOS:32, 33 and 34,
(c) an isolated antibody that binds to Plexin-A1 comprising heavy chain variable region CDRs comprised in SEQ ID NOS: 41 and light chain variable regions CDRs comprised in SEQ ID NOS:42, and
(d) an isolated antibody that binds to Plexin-A1 comprising heavy chain variable region CDRs comprised in SEQ ID NOS: 43 and light chain variable regions CDRs comprised in SEQ ID NOS:44.
US Pat. No. 10,688,179

TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS

1. A method for treating a patient having core symptoms of autism spectrum disorder (ASD), the method comprising administering to the patient one or more single unit oral dosage forms per day, each of the one or more single unit dosage forms comprising, in combination, inositol and an extended release clonidine or extended release guanfacine, wherein the inositol is cumulatively provided in an amount of at least 12,000 mg per day and wherein the method treats the patient's core symptoms of ASD.
US Pat. No. 10,689,460

PCSK9 ANTIBODY PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

Incube Labs, LLC, San Jo...

1. A method for reducing a low-density lipoprotein cholesterol (LDL-C) level in a patient having hypercholesterolemia, the method comprising: providing a solid anti-proprotein convertase subtilsin-kexin type 9 (PCSK9)-antibody (AP-antibody) dosage shaped as a tissue penetrating member, wherein the AP-antibody is selected from the group consisting of Alirocumab, Evolocumab and Bococizumab and wherein a dose of AP-antibody in the solid AP dosage is in a range from about 1 to 15 mg; penetrating the solid dosage AP-antibody into an intestinal wall after oral ingestion by the application of force on the tissue penetrating member such that the tissue penetrating member is retained in the intestinal wall or surrounding tissue; and releasing the AP-antibody into the blood stream from the solid dosage AP-antibody in the intestinal wall or surrounding tissue to reduce the LDL-C level by binding of PCSK9 molecules by the released dosage of PCSK9 antibody.
US Pat. No. 10,689,717

METHODS AND COMPOSITIONS FOR TARGETED SINGLE-STRANDED CLEAVAGE AND TARGETED INTEGRATION

Sangamo Therapeutics, Inc...

1. A method of making a point mutation in a genomic sequence in an isolated cell, the method comprising introducing a polynucleotide encoding an artificial nuclease into the cell, the artificial nuclease comprising(i) first and second cleavage domains from an endonuclease, wherein the first cleavage domain is catalytically inactive and the second cleavage domain is catalytically active; and
(ii) a DNA-binding molecule that is heterologous to the first and second cleavage domains, and further wherein the DNA-binding molecule of the nuclease binds to a target sequence in a double-stranded genome and the nuclease induces a site-specific single-stranded break at or near the target sequence in the double-stranded genome wherein the genomic sequence is modified.
US Pat. No. 10,688,180

COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER

BRISTOL-MYERS SQUIBB COMP...

1. A method of treating cancer in a human patient diagnosed with non-small cell lung cancer (NSCLC), castrate resistant prostate cancer (CRPC) and/or melanoma, the method comprising administering to the patient an anti-KIR antibody which blocks the activity of at least one of the inhibitory KIR2DL1, KIR2DL2 and KIR2DL3 receptors and an anti-CTLA-4 antibody which blocks the activity of CTLA-4, (A) for at least one cycle during an induction phase, followed by (B) at least one cycle during a maintenance phase, wherein:(a) the anti-KIR antibody comprises the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequences set forth in SEQ ID NO:3, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequences set forth in SEQ ID NO:5;
(b) the anti-CTLA-4 antibody comprises the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequences set forth in SEQ ID NO:19, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequences set forth in SEQ ID NO:20; and
(c) the anti-KIR antibody is administered at a dose of 0.1, 0.3, or 1 mg/kg, and the anti-CTLA-4 antibody is administered at a dose of 3 or 10 mg/kg during both phases.
US Pat. No. 10,689,718

HEV ASSAY

Roche Molecular Systems, ...

1. A kit for simultaneously detecting the presence or absence of genotypes 1, 2, 3, and 4 of HEV, if present in a biological sample, comprising:(a) a template-dependent DNA polymerase, nucleotides;
(b) one non-degenerate forward primer comprising SEQ ID NO: 6 and at least one non-degenerate reverse primer comprising a sequence selected from the group consisting of SEQ ID NOs: 11, 13, and 14, wherein the one non-degenerate forward primer and the at least one non-degenerate reverse primer are capable of simultaneously amplifying genotypes 1, 2, 3, and 4 of HEV; and
(c) at least one detection probe comprising a fluorophore, wherein the at least one detection probe is capable of binding to amplified genotypes 1, 2, 3, and 4 of HEV from step (b).
US Pat. No. 10,688,181

CANCER TREATMENT COMBINATIONS

THE REGENTS OF THE UNIVER...

1. A method of treating an ROR-1 expressing cancer or a cancer susceptible to a BTK antagonist in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and an anti-ROR-1 antibody, wherein said anti-ROR-1 antibody comprises a humanized heavy chain variable region and a humanized light chain variable region, wherein said humanized heavy chain variable region comprises the sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and wherein said humanized light chain variable region comprises the sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
US Pat. No. 10,689,719

BIFIDOBACTERIUM LONGUM

PrecisionBiotics Group Li...

1. A pharmaceutical ingestable carrier comprising more than 106 CFU per gram of the ingestible carrier of an isolated strain of Bifidobacterium longum AH121A deposited at NCIMB with accession number NCIMB 41675, wherein the pharmaceutical ingestable carrier is a tablet, and wherein the strain induces a ratio of interleukin-10 to interleukin-12 of at least 10 in a peripheral blood mononuclear cell co-incubation assay.
US Pat. No. 10,688,182

MONOCLONAL ANTIBODIES THAT BIND TO SSEA4 AND USES THEREOF

CHO Pharma USA, Inc., Wo...

1. An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 33, a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 34, a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 35, a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 42, a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 43, and a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 44,wherein the monoclonal antibody or antigen-binding fragment specifically binds to stage-specific embryonic antigen 4.
US Pat. No. 10,688,183

STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB

Coherus Biosciences, Inc....

1. A stable aqueous pharmaceutical composition comprising:a) adalimumab;
b) at least one of succinate, histidine, phosphate, tartrate, maleate, and citrate buffer;
c) sorbitol; and
d) a surfactant,wherein i) said buffer does not comprise a combination of citrate and phosphate, ii) the composition is free of mannitol and sodium chloride, and iii) the composition has a pH of about 5 to about 5.5.
US Pat. No. 10,689,721

CASE HARDENING STEEL AND CARBURIZED COMPONENT OBTAINED THEREFROM

DAIDO STEEL CO., LTD., A...

1. A carburized part obtained by working a case hardening steel into a shape of a part by cold forging, followed by subjecting to carburizing and quenching, the case hardening steel satisfying the following Expression (1) representing a maximum deformation resistance ?MAX in MPa and a DI value, the maximum deformation resistance ?MAX in MPa being obtained when a test piece which has a size of ? 15×22.5 mm and is cut out from a material after spheroidizing, is subjected to compressive deformation by cold forging at a compression ratio of 70% in a state that an end surface thereof is restrained, and the DI value being obtained from a Jominy quenching test:?MAX<12.8×DI+745  Expression (1),wherein a total amount of TiC, AlN and ZrC, which are precipitate particles, is 4.5×10?10 moles or less per 1 mm2 of grain boundary area of prior austenite grains after the carburizing and quenching, and the case hardening steel having a composition consisting essentially of, in terms of % by mass:0.10% to 0.30% of C;
0.01% to 1.50% of Si;
0.40% to 1.50% of Mn;
0.01% to 0.10% of S;
0.03% or less of P;
0.05% to 1.00% of Cu;
0.05% to 1.00% of Ni;
0.01% to 1.39% of Cr;
0.01% to 0.50% of Mo;
0.001% or less of Nb;
0.005% to 0.050% of s-Al;
0.005% to 0.030% of N;
0.001% to 0.150% of Ti; and
0.000% to 0.300% of Zr,
and optionally: 0.001% to 0.010% of B,
with the remainder being Fe and inevitable impurities,
wherein [Ti], [Zr] and [N] which respectively represent contents of Ti, Zr and N satisfy the following Expression (2):
|[Ti]/47.9+[Zr]/91.2+[N]/14|/100?3.5×10?6 mol/g  Expression (2),
wherein, in a structure thereof after the carburizing and quenching, an average crystal grain size number of the prior austenite grains is No. 5.9 or less.
US Pat. No. 10,692,797

THERMAL INTERFACE MATERIALS WITH LOW SECANT MODULUS OF ELASTICITY AND HIGH THERMAL CONDUCTIVITY

Laird Technologies, Inc.,...

1. An interface material comprising a matrix or base resin loaded with a filler, wherein:the interface material has a secant modulus of elasticity of no more than 620 kilopascals (kPa) at 50% strain for 1.5 millimeter (mm) initial thickness material;
a ratio of the interface material's secant modulus of elasticity to thermal conductivity falls within a range from about 0.46 to about 64.6 and/or a ratio of the interface material's thermal conductivity to secant modulus of elasticity falls within a range from about 0.015 to about 2.18;
the interface material is a bulk putty, a thermally-conductive gap filler pad, or a thermally-conductive gap filler sheet material;
the matrix or base resin is loaded with the filler such that the interface material includes at least 80 weight % of the filler; and
the matrix or base resin comprises:
a polydimethylsiloxane (PDMS); or
silicone polymer with platinum catalyst and crosslinker; or
a process oil.
US Pat. No. 10,689,465

EXTERNAL DONOR FOR OLEFIN POLYMERIZATION

Indian Oil Corporation Li...

1. A process of polymerization of olefins, said process comprising the step of contacting an olefin having C2 to C20 carbon atoms under a polymerizing condition with a catalyst system comprising an external electron donor composition consisting essentially of a dibutyl ether as activity limiting agent in the range of 30 to 50 mole percent along with an alkoxy silane as selectivity controlling agent,wherein the polymerization process is carried out at a temperature of around 70° C., and when the temperature during polymerization process elevates to 85° C. to 130° C., the dibutyl ether present in the external electron donor composition acts as an activity limiting agent and reduces the polymerization activity of the catalyst without affecting the polymer properties.
US Pat. No. 10,688,185

PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

AXSOME THERAPEUTICS, INC....

1. A method of treating migraine comprising: selecting a human migraine patient with a history of inadequate response to prior migraine treatments, and orally administering a dosage form to the migraine patient, wherein the dosage form comprises a combination of: 1) a complex of meloxicam with a sulfobutyl ether ?-cyclodextrin (SBE?CD), 2) a bicarbonate, and 3) a rizatriptan, wherein the human migraine patient experiences reduction in vomiting that lasts at least 24 hours after the dosage form is orally administered to the human migraine patient.
US Pat. No. 10,689,723

FERRITIC STAINLESS STEEL AND HEAT-RESISTANT MEMBER

DAIDO STEEL CO., LTD., N...

1. A ferritic stainless steel, consisting of, in mass %:0.001%?C?0.020%,
0.05%?Si?0.50%,
0.1%?Mn?1.0%,
15.0%?Cr?25.0%,
Mo<0.50%,
1.4%?W?2.5%, and
0.01%?Nb?0.40%, and
at least one member selected from the group consisting of:
Ni?2.0%,
Ti?0.50%,
Ta?0.50%,
B?0.0080%,
Mg?0.0100%, and
Ca?0.0100%,
with a balance being Fe and unavoidable impurities,
having a content of coarse Laves phase having a diameter of 0.50 ?m or more being 0.1% or less,
having an average grain size being 30 ?m or more and 200 ?m or less, and
having a solid-solution temperature of a Laves phase of 950° C. or less.
US Pat. No. 10,691,775

BIOINFORMATICS SYSTEMS, APPARATUSES, AND METHODS EXECUTED ON AN INTEGRATED CIRCUIT PROCESSING PLATFORM

EDICO GENOME, CORP., La ...

1. A system for performing a bioinformatics analysis on genomic data from a subject using genetic reference sequence data, where each of the genomic data and the genetic reference sequence data represent a sequence of nucleotides, the system comprising:a cloud computing cluster having one or more servers;
a memory associated with the one or more servers for storing the genomic data and the genetic reference sequence data; and
a field programmable gate array (FPGA) housed in at least one of the one or more servers, the FPGA comprising a set of hardwired digital logic circuits, the hardwired digital logic circuits being interconnected by a plurality of physical electrical interconnects, one or more of the plurality of physical electrical interconnects comprising a memory interface to access the memory, the hardwired digital logic circuits being arranged as a set of processing engines, each processing engine being formed of a subset of the hardwired digital logic circuits to perform one or more steps in the bioinformatics analysis on the genomic data, the set of processing engines comprising a first wired configuration to access the genomic data of the subject and the genetic reference sequence data, compare the sequence of nucleotides in the genomic data to the sequence of nucleotides of the genetic reference sequence data to determine one or more similarities or differences between the sequence of nucleotides in the genomic data and the sequence of nucleotides in the genetic reference sequence data to produce results data, the results data being storable in the memory; and
the cloud computing cluster being configured to access the memory, retrieve, and process the results data to generate one or more diagnostic, prophylactic and/or therapeutic evaluations based on the one or more similarities or differences.
US Pat. No. 10,688,186

ANTI-CD3 ANTIBODY FORMULATIONS

Tiziana Life Sciences PLC...

1. A formulation comprising: anti-CD3 antibody comprising a heavy chain amino acid sequence comprising the amino acid sequence of SEQ ID NO: 10 and a light chain amino acid sequence comprising the amino acid sequence of SEQ ID NO: 11, sodium acetate trihydrate, sodium chloride, polysorbate 80, trehalose, and methionine.
US Pat. No. 10,688,187

LIQUID PHARMACEUTICAL COMPOSITION OF ADALIMUMAB

INTAS PHARMACEUTICALS LTD...

1. An aqueous pharmaceutical formulation of Adalimumab comprising:a) 50 mg/mL Adalimumab,
b) 15 mM glycine buffer,
c) 9.5% sucrose, and
d) 0.1% Polysorbate 80 at pH 5.2.
US Pat. No. 10,687,675

ABSORBENT TOWEL PAPER WEB PRODUCTS COMPRISING NANO-FILAMENTS

Mercer International Inc....

11. A differential density absorbent towel paper web comprising at least one ply, said differential density absorbent towel paper web comprising:(a) from about 45% to about 90% by weight of the dry fiber basis of said differential density absorbent towel paper web of a softwood pulp fiber mixture, said softwood pulp fiber mixture comprising:
1) from about 20% to about 89.9% by weight of the dry fiber basis of said differential density absorbent towel paper web of softwood pulp fibers;
2) from about 0.05% to about 20% by weight of the dry fiber basis of said differential density absorbent towel paper web of a blend of cellulose micro-filaments and cellulose nano-filaments, said blend of cellulose micro-filaments and cellulose nano-filaments comprising:
A) at least about 40% by weight of said blend of cellulose micro-filaments and cellulose nano-filaments of cellulose micro-filaments and cellulose nano-filaments;
B) at least about 10% by weight of said blend of cellulose micro-filaments and cellulose nano-filaments of intact fibrillated fibers; and
C) at least about 5% by weight of said blend of cellulose micro-filaments and cellulose nano-filaments of cellulosic fines; and,
b) from about 0.05% to about 5.0% by weight of the dry fiber basis of said differential density absorbent towel paper web of a strengthening additive; and,
c) from about 10% to about 55% by weight of the dry fiber basis of said differential density absorbent towel paper web of a hardwood pulp fiber mixture.
US Pat. No. 10,688,188

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

1. A method comprising:providing a composition comprising a fluorinated copolymer dissolved in an organic solvent, the fluorinated copolymer comprising tetrafluoroethylene and at least one functional group selected from the group consisting of acetate, alcohol, amine, and amide;
introducing the composition into a patient; and
hardening the fluorinated copolymer in the patient by diffusing the organic solvent into the patient.
US Pat. No. 10,688,701

TRANSFER SHEET, METHOD FOR PRODUCING TRANSFER SHEET, OPTICAL LAMINATE, AND METHOD FOR PRODUCING OPTICAL LAMINATE

FUJIFILM Corporation, To...

1. A transfer sheet comprising, in order:a cured liquid crystal composition layer;
a block layer; and
a thermoplastic welded layer,
wherein the block layer includes a urethane (meth)acrylate polymer,
the thermoplastic welded layer and the block layer are in direct contact with each other, and
the thermoplastic welded layer includes a thermoplastic resin and an ultraviolet curable resin.
US Pat. No. 10,689,470

STATIC SEALS, COMPOSITIONS, AND METHODS OF MAKING THE SAME

COOPER-STANDARD AUTOMOTIV...

1. A static sealing member comprising:a composition comprising a silane-crosslinked polyolefin elastomer having a density less than 0.90 g/cm3 and a crystallinity of from about 5% to about 20%,
wherein from about 1 wt % to about 35 wt % of the silane-crosslinked polyolefin elastomer is a polypropylene filler having a crystallinity greater than 40%,
wherein the silane-crosslinked polyolefin elastomer does not display a Mullins effect or a Payne effect;
wherein the silane-crosslinked polyolefin elastomer and the static sealing member are thermosets; and
wherein the static sealing member exhibits a compression set of from about 5.0% to about 35.0%, as measured according to ASTM D 395 (22 hrs @ 70° C.).
US Pat. No. 10,688,445

ZEOLITE MEMBRANE STRUCTURE AND METHOD FOR PRODUCING SAME

NGK Insulators, Ltd., Na...

1. A zeolite membrane structure comprising:a porous support, and
a zeolite membrane, and
the zeolite membrane having a first zeolite layer located in a surface of the porous support, and a second zeolite layer located outside of the surface of the porous support and integrally formed with the first zeolite layer,
the porous support having an outermost layer in which the first zeolite layer is located,
an average thickness of the first zeolite layer being less than or equal to 5.4 micrometers, and
a 50% diameter in a volume-accumulated pore diameter distribution of the outermost layer measured by use of a pore diameter distribution measurement apparatus being greater than or equal to 0.050 micrometers and less than or equal to 0.150 micrometers.
US Pat. No. 10,689,471

MICRODENSE SEALS, COMPOSITIONS, AND METHODS OF MAKING THE SAME

COOPER-STANDARD AUTOMOTIV...

1. A microdense sealing member comprising:a composition comprising a foamed silane-crosslinked polyolefin elastomer having a density less than 0.70 g/cm3, a tensile strength ranging from 5.0 to 7.6 MPa as measured according to ASTM D412, a Shore A hardness ranging from 60 to 87 as measured according to ASTM D412, and a crystallinity of from about 5% to about 20%,
wherein from about 1 wt % to about 20 wt % of the foamed silane-crosslinked polyolefin elastomer is a polypropylene filler having a crystallinity greater than 40%,
wherein the foamed silane-crosslinked polyolefin elastomer does not display a Mullins effect or a Payne effect;
wherein the foamed silane-crosslinked polyolefin elastomer and the microdense sealing member are thermosets; and
wherein the microdense sealing member exhibits a compression set of from about 40.0% to about 78.0%, as measured according to ASTM D 395 (22 hrs @ 70° C.).
US Pat. No. 10,688,190

MEDICATION SYSTEM

1. A method for treating burned human skin or wounded human skin on a human in need thereof consisting essentially of administering via a patch to the human skin in need thereof therapeutically effective amounts of isolated cannabigerol, fibrinogen, collagen, and hyaluronic acid to effectively treat the human skin that has been burned or wounded on the human in need thereof.
US Pat. No. 10,689,472

CROSSLINKABLE FLUOROPOLYMERS

SOLVAY SPECIALITY POLYMER...

1. A crosslinkable fluoropolymer [polymer (FC)] comprising:first recurring units derived from vinylidene fluoride (VDF),
from 10% to 50% by moles, with respect to the total moles of recurring units of said polymer (FC), of second recurring units derived from trifluoroethylene (TrFE), and
from 0.01% to 10% by moles, with respect to the total moles of recurring units of said polymer (FC), of third recurring units derived from at least one functional hydrogenated monomer (H?F), said third recurring units comprising a pendant side chain comprising an end group (E) of any of formulae (III-A) to (V-A):
—O—C(O)—C(R3)?CR1R2  (III-A)
—O—C(O)—NH—C(O)—C(R3)?CR1R2  (IV-A)
—O—C(O)—Z—C(R3)?CR1R2  (V-A)
wherein each of R1, R2 and R3, equal to or different from each other, is independently a hydrogen atom or a C1-C3 hydrocarbon group, and Z is a bonding group of any of formulae (j) and (jj):
—NH—X—O—C(O)—  (j), and
—NH—X—NHC(O)O—X?—O—C(O)—  (jj)
wherein X and X?, equal to or different from each other, are independently hydrocarbon groups selected from the group consisting of C1-C20 aliphatic groups, C5-C40 cycloaliphatic groups and C6-C50 aromatic, alkylaromatic and heteroaromatic groups.
US Pat. No. 10,687,934

SEROUS MEMBRANE FOR OCULAR SURFACE DISORDERS

Carlos A. Alvarado, Plan...

1. A method for inducing restoration of diseased or defective ocular tissues, said method comprising:applying a transparent biocompatible conjunctival implant as a graft in direct contact with a diseased or defective ocular surface of a patient's eye,
wherein the conjunctival implant consists of porcine small intestinal serosa (or serous membrane),
wherein the porcine small intestinal serosa (or serous membrane) of the conjunctival implant is utilized to induce restoration, remodeling, and repair of tissue in a variety of injuries or conditions in the cornea, the conjunctiva, and/or the eyelid due to trauma, diseases, or surgery.
US Pat. No. 10,688,191

DELIVERY OF A CHEMOTHERAPY AGENT ACROSS THE BLOOD-BRAIN BARRIER

HR BIOMED, LLC, Goshen, ...

1. A therapeutic composition capable of crossing the blood-brain barrier, the composition comprising a chemotherapy agent for the treatment of brain cancer and a cannabinoid for alleviation of side effects caused by the chemotherapy agent, wherein the chemotherapy agent is chemically linked to the cannabinoid, and wherein the cannabinoid is tetrahydrocannabivarin and the chemotherapy agent is Carmustine.
US Pat. No. 10,688,447

PROCESS FOR MANUFACTURING FLUOROPOLYMER MEMBRANES

SOLVAY SPECIALTY POLYMERS...

1. A process for manufacturing a fluoropolymer membrane, said process comprising:processing a composition (C) at a temperature of at least 100° C. thereby providing a film, wherein composition (C) comprises:
at least one fluoropolymer [polymer (F)],
a water-soluble liquid medium (MWS) that is free from dimethyl sulphoxide (DMSO) and comprises at least one solvent selected from the group consisting of diesters of formula (I-de), esteramides of formula (I-ea) and diamides of formula (I-da):
R1(O?)CO-Ade-OC(?O)R2  (I-de)
R1O(O?)C-Aea-C(?O)NR3R4  (I-ea)
R5R6N(O?)C-Ada-C(?O)NR5R6  (I-da)
wherein:
R1 and R2, equal to or different from each other, are independently selected from the group consisting of C1-C20 hydrocarbon groups;
R3, R4, R5 and R6, equal to or different from each other, are independently selected from the group consisting of hydrogen, optionally substituted C1-C36 hydrocarbon groups, wherein R3 and R4 optionally form a cyclic moiety including the nitrogen atom to which they are bound, and wherein R5 and R6 optionally form a cyclic moiety including the nitrogen atom to which they are bound, wherein each cyclic moiety is optionally substituted and/or optionally comprises one or more than one additional heteroatoms,
Ade is a C3-C10 divalent alkylene group comprising one or more ether oxygen atoms,
Aea and Ada, equal to or different from each other, are independently C3-C10 divalent alkylene groups, optionally comprising one or more ether oxygen atoms and/or one or more functional side groups;
cooling the film to a temperature below 50° C. to form a cooled film;
contacting the cooled film with a non-solvent medium (MNS) thereby providing a fluoropolymer membrane; and
optionally, drying the fluoropolymer membrane.
US Pat. No. 10,689,473

GRAFT COPOLYMER, METHOD OF PREPARING GRAFT COPOLYMER, THERMOPLASTIC RESIN COMPOSITION INCLUDING GRAFT COPOLYMER, AND MOLDED PART INCLUDING THERMOPLASTIC RESIN COMPOSITION

LG CHEM, LTD., Seoul (KR...

1. A graft copolymer, comprising:a conjugated diene rubber core; and a shell surrounding the rubber core,
wherein the shell is obtained by graft-polymerizing a (meth)acrylic acid alkyl ester compound, an aromatic vinyl compound, and a vinyl cyanide compound,
wherein, when the graft polymerization is performed, a metal salt of sorbic acid is added in an amount of 0.1 to 0.49 parts by weight based on 100 parts by weight of a total composition of the conjugated diene rubber core and the shell,
wherein the shell has a weight average molecular weight of 80,000 to 300,000 g/mol.
US Pat. No. 10,689,474

METHOD FOR PRODUCING SEMI-IPN COMPOSITE, AND METHOD FOR PRODUCING SYNTHETIC LEATHER

DIC CORPORATION, Tokyo (...

1. A method for producing a semi-IPN composite, the method comprising polymerizing a hydrophilic monofunctional acrylate (b1) and a polyfunctional acrylate (b2) in a solution of a polyurethane (A) prepared using an aliphatic polyisocyanate and/or an alicyclic polyisocyanate as a raw material,wherein the hydrophilic monofunctional acrylate (b1) comprises an amido group-containing acrylamide monomer (b1-1) and an oxyethylene group-containing acrylate monomer (b1-2), and
wherein the polymerization ratio (molar ratio) between the amido group-containing acrylamide monomer (b1-1), the oxyethylene group-containing acrylate monomer (b1-2), and the polyfunctional acrylate (b2) is within the range of (b1-1)/(b1-2)/(b2)=50/49.5/0.5 to 89/1/10.
US Pat. No. 10,691,013

EXTREME ULTRAVIOLET LITHOGRAPHY SYSTEM HAVING CHUCK ASSEMBLY AND METHOD OF MANUFACTURING THEREOF

Applied Materials, Inc., ...

1. A method of manufacturing a semiconductor device comprising:directing extreme ultraviolet (EUV) light from an EUV light source through a reflective lens system;
interposing an EUV mask in the reflective lens system, the EUV mask having a substrate and a multi-layer stack forming a Bragg reflector, the multi-layer stack and the substrate having a thermally conducting smooth substrate with a predetermined substrate flatness held on a surface of a chuck being thermally conducting and smooth having a predetermined chuck flatness; and
reflecting a pattern of the EUV mask on a semiconductor substrate for forming the semiconductor device, wherein interposing the EUV mask held on the surface of the chuck includes interposing the EUV mask held on the surface of the chuck having a textured mounting surface, wherein the textured mounting surface has mesas, grooves, holes, or a combination thereof.
US Pat. No. 10,688,196

CROSS-LINKING AGENTS OF COLLAGEN FIBERS FOR THE USE IN THE TREATMENT OF CORNEAL ECTASIA

SOOFT ITALIA SPA, Monteg...

1. A method of using a complex of riboflavin with hydroxypropylated ?-cyclodextrins as photosensitizer in the riboflavin-UV mediated cross-linking of corneal collagen fibers, wherein the weight ratio of hydroxypropyl-?-cyclodextrin to riboflavin is 26, andwherein the method comprises administering the complex to a patient in need thereof, and wherein said riboflavin-UV mediated cross-linking is performed with ultraviolet-A (UVA) irradiation at a wavelength of 366 nm and at different incident light intensity selected from a group consisting of 99 ?W/cm2, 233 ?W/cm2, and 633 ?W/cm2.
US Pat. No. 10,688,197

NON-ALCOHOLIC FATTY LIVER REGULATOR 14-3-3 PROTEIN

Korea University Research...

1. A method of screening a drug for treating a non-alcoholic fatty liver and treating the non-alcoholic fatty liver, the method comprising:a contacting step of contacting 14-3-3? proteins into contact with a candidate material together with the PPAR?2 proteins in vitro;
a measuring step of measuring a change in binding of the 14-3-3? proteins to the PPAR?2 proteins by the candidate material, wherein when the candidate material down-regulates the binding of the 14-3-3? proteins to the PPAR?2 proteins, the candidate material is selected as a screened drug having an effect on treating the non-alcoholic fatty liver; and
an administering step of administering an effective amount of the screened drug, which down-regulates the binding of the 14-3-3? proteins to the PPAR?2 proteins and thus having the effect on treating the non-alcoholic fatty liver, to a subject in need thereof.
US Pat. No. 10,689,479

CURABLE COMPOSITION, ADHESIVE, ARTICLE HAVING COATING LAYER, FIBER-REINFORCED COMPOSITE MATERIAL AND CURABLE COMPOSITION KIT

Mitsubishi Chemical Corpo...

1. A curable composition, comprising:a thiol compound (A) having at least two thiol groups in a molecule thereof;
an isocyanate compound (B) having at least two isocyanate groups in a molecule thereof;
a phosphine compound (C);
an aromatic sulfonic acid (D) having an acid dissociation constant (pKa) of 3 or less relative to water; and
a Michael acceptor (E), wherein
an amount of the phosphine compound (C) is greater than 0% by mass and 1.3% by mass or less based on 100% by mass of the curable composition.
US Pat. No. 10,688,199

THERANOSTIC BUBBLE PREPARATION (TB), AND METHOD FOR USING SAME

TEIKYO UNIVERSITY, Tokyo...

1. A theranostic bubble preparation comprising:bubbles that enable diagnostics and therapeutics of a tissue of interest through an action of diagnostic ultrasound and an action of low intensity therapeutic ultrasound,
the bubbles each comprising a coating of a lipid and a gas encapsulated in an inner cavity defined by the coating,
wherein:
the lipid forming the coating is an anionic lipid including distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (DSPE-PEG) at a molar ratio of 30-36:54-60:10,
the gas includes at least one of perfluoropropane, perfluorobutane, perfluoropentane, or perfluorohexane, or a mixed gas thereof; and
the bubbles each have a diameter ranging from 500 nm to 5 ?m.
US Pat. No. 10,689,737

HOT-ROLLED STEEL SHEET

NIPPON STEEL CORPORATION,...

1. A hot-rolled steel sheet comprisinga chemical composition represented by, in mass %,
C: 0.010% to 0.100%,
Si: 0.30% or less,
Mn: 0.40% to 3,00%,
P: 0.100% or less,
S: 0.030% or less,
Al: 0,010% to 0.500%,
N: 0.0100% or less,
Cr: 0.05% to 1.00%,
Nb: 0.003% to 0.050%,
Ti: 0.003% to 0.200%,
Cu: 0.0% to 1.2%,
Ni: 0.0% to 0.6%,
Mo: 0.00% to 1.00%,
V: 0.00% to 0.20%,
Ca: 0.0000% to 0.0050%,
REM: 0.0000% to 0.0200%,
B: 0.0000% to 0.0020%, and
a balance: Fe and impurities,whereinrelationships represented by Expression 1 and Expression 2 are satisfied,
Expression 1: 0.005 5?[Si]/[Cr]?2.000
Expression 2: 0.5?[Mn]/[Cr]?20.0
wherein [Si], [Cr], and [Mn] in the Expression 1 and Expression 2 each represent a content, in mass %, of each of the elements, respectively, and
wherein a proportion of grains having an intragranular misorientation of 5° to 14° in all grains is 20% or more by area ratio, wherein each grain is defined as an area which is surrounded by a boundary having a misorientation of 15° or more, and wherein each grain has a circle-equivalent diameter of 0.3 ?m or more,
the hot-rolled steel sheet comprising a microstructure represented by
a volume ratio of cementite: 1.0% or less,
an average grain diameter of cementite; 2.00 ?m or less,
a concentration of Cr contained in cementite; 0.5 mass % to 40.0 mass %,
a proportion of cementite having a grain diameter of 0.5 ?m or less and an aspect ratio of 5 or less in all cementite: 60 vol % or more,
an average grain diameter of a composite carbide of Ti and Cr: 10.0 nm or less, and
a number density of the composite carbide of Ti and Cr: 1.0×1013/mm3 or more.
US Pat. No. 10,688,201

HEAT-INDUCED RADIOCHEMICAL LABELING OF AN IRON OXIDE NANOPARTICLE

The General Hospital Corp...

1. A method of synthesizing a radiolabeled nanoparticle, the method comprising:(i) heating a solution to a predetermined temperature range, the solution including an unlabeled nanoparticle and at least one radioactive metal ion, the unlabeled nanoparticle including an iron oxide and a polymer coating, the at least one radioactive metal ion being configured to directly bind to the iron oxide of the unlabeled nanoparticle to form a radiolabeled nanoparticle,
wherein the predetermined temperature range is about 80° C. to about 150° C., and
wherein the unlabeled nanoparticle and the radiolabeled nanoparticle are substantially physically identical except for the resulting radioactivity of the radiolabeled nanoparticle;
(ii) adding a stripping agent to the solution to complex with non-bound radioactive metal ions remaining in the solution; and
(iii) separating the complexed stripping agent from the radiolabeled nanoparticle.
US Pat. No. 10,689,483

PROCESS FOR PREPARING POLYALKENAMERS FOR PACKAGING APPLICATIONS

Evonik Operations GmbH, ...

1. A process for producing a polyalkenamer-containing composition, comprising the steps of:a) converting at least one cycloalkene by ring-opening metathetic polymerization, in the presence of a chain transfer agent, to obtain a polyalkenamer-containing product-mixture,
b) converting the product-mixture into solid form,
c) granulating or pulverizing the product-mixture in solid form to particles prior to step d), and
d) working up the product-mixture to remove the at least one cycloalkene monomer and/or an oligomer of the at least one cycloalkene to obtain the polyalkenamer-containing composition, wherein
step d) is effected by extraction in a solvent mixture comprising at least one solvent 1 and at least one solvent 2, where the solubility parameter ? of the solvents 1 is not more than 20.07 MPa1/2 and the solubility parameter ? of the solvents 2 is at least 20.27 MPa1/2.
US Pat. No. 10,688,202

METAL(LOID) CHALCOGEN NANOPARTICLES AS UNIVERSAL BINDERS FOR MEDICAL ISOTOPES

Memorial Sloan-Kettering ...

1. A method of preparing medical isotope labeled metal(loid) chalcogen nanoparticles, the method comprising steps of:supplying a reaction mixture comprising:
metal(loid) chalcogen nanoparticles selected from the group consisting of metalloid chalcogen nanoparticles and metal(loid) chalcogen-coated metal nanoparticles, and
medical isotopes selected from the group consisting of PET-active radioisotopes, SPECT-active radioisotopes, MRI-active metals, and therapeutic radioisotopes,
which reaction mixture is substantially free of chelator; and
maintaining the reaction mixture under conditions and for a time sufficient for the medical isotopes to directly bind to the metal(loid) chalcogen nanoparticles, thereby forming the medical isotope labeled metal(loid) chalcogen nanoparticles
wherein the conditions comprise heating the reaction mixture to a temperature of equal to or greater than 25° C.
US Pat. No. 10,689,486

RESIN PRODUCED BY POLYCONDENSATION, AND RESIN COMPOSITION

MITSUBISHI GAS CHEMICAL C...

1. A polyester resin, comprising:(i) as dihydroxy component, 63 to 81 mol % of a structural unit derived from a 2,2?-bis(2-hydroxyethoxy)-1,1?-binaphthalene
and 9 to 27 mol % of a structural unit derived from a 9,9?-bis[4-(2-hydroxyethoxy)phenyl]fluorene
and
(ii) as dicarboxylic acid component, a structural unit derived from dimethyl terephthalate (DMT) or dimethyl 2,6-naphthalenedicarboxylate (NDCM);
wherein the polyester resin has a refractive index of 1.652 to 1.658, as measured by dissolving the polyester resin in methylene chloride to produce a cast film, wherein the refractive index is measured by a refractometer with the refractive index measured at 25° C. and at 589 nm (d line).
US Pat. No. 10,688,718

PRODUCTION AND USE OF POROUS BEAD POLYMERS IN 3D PRINTING USING THE BINDER JETTING METHOD

Evonik Operations GmbH, ...

1. A process for producing three-dimensional objects from a powder bed by means of a binder jetting process comprising multiple repetition of the process steps:a) selective application of a binder and subsequent or simultaneous hardening of this binder in the powder bed; and
b) application of a new powder layer on the surface;
wherein the powder bed comprises at least one type of porous polymer particles, characterized in that these porous particles have a diameter between 10 and 500 ?m and in that these porous particles comprise between 5 and 20 vol % of pores.
US Pat. No. 10,688,462

MICROCAPSULES COMPRISING ACTIVE INGREDIENTS AND A METAL OXIDE SHELL, A METHOD FOR THEIR PREPARATION AND USES THEREOF

SOL-GEL TECHNOLOGIES LTD....

1. A process of preparing microcapsules comprising a core material encapsulated by a metal oxide shell, said process comprising:(a) preparing an oil-in-water emulsion by emulsification of an oily phase that comprises a core material, in an aqueous phase, wherein one or both of the oily phase and the aqueous phase comprise a sol-gel precursor;
(b) adding metal oxide nanoparticles to said aqueous phase prior to the preparation of the emulsion of step (a), or adding the metal oxide nanoparticles during the preparation of the emulsion of step (a) or adding the metal oxide nanoparticles after the preparation of the emulsion of step (a); and
(c) applying conditions to obtain microcapsules;
wherein said core material comprises a pharmaceutically, cosmetically, or agrochemically active ingredient, wherein the active ingredient is in a solid form and dispersed in the core, and wherein said metal oxide is selected from silica, titania, zirconia, ZnO, and mixtures thereof.
US Pat. No. 10,689,488

METHOD FOR PREPARING POLYCARBONATE POLYOL AND COMPOSITION COMPRISING THE POLYCARBONATE POLYOL

INDUSTRIAL TECHNOLOGY RES...

1. A polycarbonate polyol composition, comprising:polycarbonate polyol, and
a plurality of nanoscale silicate platelets having 10,000 to 20,000 (units/per platelet) of metal cations on surfaces thereof,
wherein the polycarbonate polyol has a viscosity from 265 to 1520 cps.
US Pat. No. 10,689,744

METHOD AND ARRANGEMENT FOR PROCESSING ARTICLES

Quintus Technologies AB, ...

1. A method for processing at least one article in an arrangement comprising a pressure vessel, a furnace chamber provided inside the pressure vessel, and a load compartment arranged inside the furnace chamber, wherein the method comprises:performing a hot isostatic pressing (HIP) operation, the HIP operation including
providing at least one article to be processed inside the load compartment;
feeding a pressure medium into the pressure vessel via a pressure medium feeding device and increasing a pressure in the load compartment;
increasing a temperature in the load compartment;
maintaining the increased temperature at a first predetermined temperature level (T1) for a selected period of time (t1); and
maintaining the increased pressure at a first predetermined pressure level (P1) for a selected period of time (t2), and
performing a case hardening operation subsequent to the performing the HIP operation, the case hardening operation including
changing the temperature from the first predetermined temperature level to a second predetermined temperature level (T2);
feeding a carbon-containing gas into the pressure vessel via a gas feeding device that is separate from the pressure medium feeding device;
maintaining the second predetermined temperature level for a selected period of time (t3);
reducing the temperature in the load compartment; and
discharging the pressure medium from the pressure vessel and reducing the pressure in the load compartment.
US Pat. No. 10,689,745

SYSTEM AND METHOD FOR SURFACE HARDENING OF REFRACTORY METALS

IAP Research, Inc., Dayt...

1. An object, comprising:a) an inner region which contains zirconium or a zirconium based alloy that is 98-100% pure zirconium and 0-2% trace impurities,
b) an outer region, adjacent to and outside the inner region, which contains zirconium or a zirconium based alloy that is 98-100% pure zirconium and 0-2% trace impurities; and carbon;
wherein said outer region comprises a lattice having said outer region, said outer region being formed such that a crystal structure of said zirconium or said zirconium based alloy in both said inner region and said outer region has not changed as a result of said carbon being diffused therein and wherein said carbon is diffused in said lattice of said outer region without co-diffusion of oxygen, hydrogen or sulfur as contaminants;
said inner region has no carbon levels above the trace elements found in said zirconium or said zirconium based alloy and has a hardness that is less than a hardness of said outer region and is integral with said outer region;
said outer region of a phase of carbides of said zirconium or said zirconium based alloy having a thickness of between 5 to 100 microns.
US Pat. No. 10,689,490

METHOD FOR PRODUCING SIOH-FUNCTIONAL POLYSILOXANES

WACKER CHEMIE AG, Munich...

1. A continuous process for producing organopolysiloxanes having an OH content of 3.0-10.0% by weight, comprising:continuously metering into a reactor, silanes of the formula I
R1mSiR2nXo  (I),
in which
R1 each independently is a C1-C18-hydrocarbon radical,
R2 each independently is a C1-C6-alkoxy radical,
X is a chlorine or bromine radical,
m is 1, 2 or 3,
n is 0, 1, 2 or 3, and
o is 0, 1, 2 or 3,
with the proviso that 4?m=n+o, and that in at least 30 mol % of the silanes of the formula I, n and o are simultaneously other than 0,
and continuously metering water, and non-polar solvent soluble to an extent of not more than 1 g in 1 L of water at 20° C. and 1 bar, into the reactor to form a reaction mixture, and continuously discharging the reaction mixture from the reactor.
US Pat. No. 10,688,466

METHOD AND SYSTEM FOR EXTRACTING STRANDED GAS FROM UNDERWATER ENVIRONMENTS, CONVERTING IT TO CLATHRATES, AND SAFELY TRANSPORTING IT FOR CONSUMPTION

CENTURY FATHOM, INC., Se...

1. A method for extracting natural gas from a hydrocarbon reservoir of oil and gas in a subterranean environment comprising the steps of(a) optionally drilling a well into the ocean floor to extract hydrocarbons as a natural gas or oil and natural gas mixture;
(b) extracting hydrocarbons as a natural gas or oil and natural gas mixture;
(c) separating oil from the natural gas in a separator;
(d) optionally transporting, pumping or piping the oil to the ocean surface;
(e) cleaning the natural gas of debris;
(f) transporting, pumping or piping the natural gas into a subsea gas/clathrate hydrate processing facility;
(g) transforming the natural gas so that it forms solid hydrates; and
(h) assembling the solid hydrates into a shipping container suitable for transporting the solid hydrates to the ocean surface.
US Pat. No. 10,689,492

METHOD FOR DEWATERING A POLYMER AND THE POLYMER MADE THEREFROM

SABIC GLOBAL TECHNOLOGIES...

1. A method of dewatering a wet polymer composition comprising:introducing the wet polymer composition comprising an interfacial polycarbonate powder via a polymer feed location to a powder conveying section of an extruder; wherein the wet polymer composition comprises greater than or equal to 1 wt % of water based on the total weight of the wet polymer composition;
venting the water through a conveying section vent to form a dry polymer composition;
adding an additive; wherein the adding comprises adding an optionally liquid additive composition comprising the additive in the powder conveying section to the dry polymer composition, wherein the adding is optionally performed under nitrogen;
melt kneading the dry polymer composition in a melt kneading section of the extruder to form a polymer melt;
introducing the polymer melt from the melt kneading section directly into a melt seal section located in a melt conveying section; and then
conveying the polymer melt in through the remaining melt conveying section of the extruder.
US Pat. No. 10,688,467

METHOD FOR ENHANCING VOLUMETRIC CAPACITY IN GAS STORAGE AND RELEASE SYSTEMS

INGEVITY SOUTH CAROLINA, ...

1. A porous gas sorbent monolith, comprising:a gas adsorbing material; including about 200 cc/L-M volume in pores about 9-27 ? size, and >about 50 cc/L-M volume in pores about 27-490 ? size, and a part density of ?0.4 g/cc,
wherein the porous gas sorbent monolith has a working gravimetric capacity of ?40 lbs/GGE and/or a volumetric capacity of <35 L/GGE.
US Pat. No. 10,689,493

THERMOSETTING RESIN COMPOSITION

SHOWA DENKO K.K., Tokyo ...

1. A thermosetting resin composition comprising (A) a polyalkenylphenol resin and (B) an aromatic polymaleimide compound, wherein the polyalkenylphenol resin (A) has in the molecule at least one each of (a1) an aromatic ring unit with an alkyl-etherified phenolic hydroxyl group and with or without a 2-alkenyl group bonded thereto, and (a2) an aromatic ring unit with a phenolic hydroxyl group and with or without a 2-alkenyl group bonded thereto, at least some of the aromatic ring units (a1) and/or (a2) having a 2-alkenyl group, each aromatic ring unit being bonded by a linking group, wherein the ratio of n to (m+n) is 15 to 50% where m is the number of aromatic ring units of (a1) and n is the number of aromatic ring units of (a2), and wherein the thermosetting resin composition comprises the polyalkenylphenol resin (A) in an amount such that the proportion of 2-alkenyl groups is 0.4 to 1.5 mol relative to 1 mol of maleimide groups in the aromatic polymaleimide compound (B) wherein the cured product of the thermosetting composition has a water absorption rate of less than or equal to 0.3%.
US Pat. No. 10,689,494

POLYMERIC SHEETS AND ARTICLES WRAPPED THEREWITH

POLYSACK FLEXIBLE PACKAGI...

1. An article comprising:a polymeric film roll configured to be used in a machine direction labeling system;
and wherein the film roll comprises: a multi-layer polymeric film formed by co-extruding an inner film layer and two outer film layers, wherein the inner film layer comprises polyethylene and the two outer film layers each comprise a blend of a polystyrene polymer and a polystyrene copolymer,
wherein the film is monoaxially stretched in a machine direction of the film roll and has a density less than 1 g/cm3, wherein the density is calculated as follows:
exposing the film to a temperature of 100° C. to shrink the film and measuring the density of the film after shrinkage,
wherein the film is shrinkable in the machine direction of the polymeric film roll by at least 15% upon exposing the film to 100° C. with a steam tunnel, and
wherein the film is shrinkable in a transverse direction of the polymeric film roll by less than 5% upon exposing the film to 100° C. with a steam tunnel.
US Pat. No. 10,688,726

METHOD FOR PRODUCING A CUSTOMISED ORTHOPAEDIC IMPLANT

Royal Melbourne Institute...

1. A method for producing a customised orthopaedic implant formed of metal, the method comprising:a. scanning a bone, the bone being a diseased bone from which a region of bone that is diseased is to be resected to obtain a three dimensional digital image of an unresected volume of the diseased bone;
b. resecting the region of bone that is diseased to leave a remaining volume of the bone from which the diseased region has been resected;
c. scanning the remaining volume of bone after the region of bone that is diseased has been resected to obtain a corresponding three dimensional digital image of the remaining volume of bone;
d. comparing the three dimensional digital image of the unresected volume of bone to the corresponding three dimensional digital image of the remaining volume of bone to estimate a volume of the region of bone that has been resected;
e. using the estimate of the volume of the region of bone that has been resected to generate a three dimensional computer model that substantially conforms to a configuration of the volume of the region of bone that was resected and is optimised to substantially restore a biomechanical function of the bone on implantation of a customised orthopaedic implant corresponding to the optimised three dimensional computer model; and
f. manufacturing the customised orthopaedic implant from the optimised three dimensional computer model, wherein the implant is configured for insertion into the region of the remaining bone from which the diseased region of bone has been resected in step b.
wherein the customised orthopaedic implant is substantially comprised of a lattice-type geometry that has a periodic arrangement and that is conformal to the resected volume of bone, and
wherein the optimisation to substantially restore the biomechanical function of the bone involves topological optimisation to provide the implant with an optimal conformal lattice-type geometry made in consideration of the anatomical function and of the properties of the bone type corresponding to the region of diseased bone that has been resected, together with patient-specific parameters and the anticipated loads to which the implant will be subjected during various typical activities and movements.
US Pat. No. 10,688,470

SEPARATIONS WITH ORGANIC MOLECULAR SOLIDS

University of Liverpool, ...

1. Use of a host material for the separation of elements or compounds,wherein the host material is an organic molecular solid with suitable cavities for accommodating a guest material to be separated, and with interconnections between the cavities to allow the guest material to diffuse through the host material,
wherein said interconnections are closed for a proportion of the time,
wherein the host comprises molecular cages prepared by the condensation of aldehydes and amines in a cycloimination reaction; and
wherein said use is effective for the separation of rare gases, or
wherein said use is effective for enantioselective separation, or
wherein said use is effective for the separation of alkane isomers or mixtures of different alkanes.
US Pat. No. 10,691,034

POLYESTER RESIN FOR TONER, METHOD FOR PRODUCING SAME, AND TONER

Mitsubishi Chemical Corpo...

1. A method for producing a polyester resin for a toner, the method comprising:polycondensing a monomer mixture comprising a polyhydric alcohol which comprises an alkylene oxide adduct of bisphenol A and ethylene glycol, and a polyvalent carboxylic acid in the presence of a compound A,
wherein the compound A is at least one compound selected from the group consisting of an ester wax comprising at least one hydrocarbon group having at least 12 carbon atoms and an oxidized polyethylene having at least 12 carbon atoms, and
wherein an amount of the polyvalent carboxylic acid and the polyhydric alcohol is set such that the number of hydroxyl groups in a monomer is 1.20 or less when the number of carboxyl groups in the monomer is 1.
US Pat. No. 10,689,497

ONE-STEP PROCESS FOR MAKING A POLYMER COMPOSITE COATING WITH HIGH BARRIER

AGENCY FOR SCIENCE, TECHN...

1. A polymeric coating suspension that comprises:a) 1.0 to 11.0 wt % of clay or silane modified clay,
b) 0.1 to 10.0 wt % of poly (acrylic acid) copolymer, which is a copolymer of acrylic acid (AA) with at least one other monomer selected from 2-ethylhexyl acrylate (EHA), ?-carboxyethyl acrylate (?-CEA), methacrylamidoethyl ethylene urea (WAM II) and ethoxylated behenyl methacrylate (?-EM),
c) 1.0 to 15.0 wt % of other polymers and
d) 70 to 97 wt % of water or mixture of water with 2-propanol.
US Pat. No. 10,689,498

CLOSED CELL FOAMS INCLUDING POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF

Tepha, Inc., Lexington, ...

1. A foam composition comprising poly-4-hydroxybutyrate (P4HB) homopolymer, wherein the foam comprises closed cells as measured by ASTM D6226-10, and wherein the foam has an open cell content of less than 50%, and wherein the P4HB homopolymer is not crosslinked.
US Pat. No. 10,691,037

PRODUCTION METHOD OF RUBBER COMPOSITION

ZEON CORPORATION, Tokyo ...

1. A production method of a rubber composition comprising a rubber component, which comprises a polyether rubber and a liquid ethylenically unsaturated nitrile-conjugated diene copolymer rubber, and a cross-linking agent, the production method comprisinga first step of mixing in a solution:
the polyether rubber dissolved in a solvent at 5 to 30 wt % concentration of the polyether rubber,
wherein the polyether rubber has, as main structural unit, oxyalkylene repeating units which are obtained by polymerizing an oxirane monomer by ring opening polymerization,
wherein the polyether rubber comprises ethylene oxide monomer units in an amount of 40 to 80 mol %; and
the liquid ethylenically unsaturated nitrile-conjugated diene copolymer rubber, wherein the liquid ethylenically unsaturated nitrile-conjugated diene copolymer rubber contains 10 to 60 wt % of ethylenically unsaturated nitrile monomer units and 40 to 90 wt % of conjugated diene monomer units,
a second step of coagulating and drying a composition containing the rubber component, which comprises the polyether rubber and the liquid ethylenically unsaturated nitrile-conjugated diene copolymer rubber, and the solvent so as to remove the solvent and obtain a solid composition, and
a third step of adding the cross-linking agent to the solid composition.
US Pat. No. 10,688,218

LARGE 3D POROUS SCAFFOLDS MADE OF ACTIVE HYDROXYAPATITE OBTAINED BY BIOMORPHIC TRANSFORMATION OF NATURAL STRUCTURES AND PROCESS FOR OBTAINING THEM

GREENBONE ORTHO S.R.L., ...

1. A biomorphic hydroxyapatite scaffold obtained from a wood having a total porosity of at least 20%, said porosity being measured after subjecting the wood to a step of pyrolysis, said scaffold having a length, measured along a direction in which a dimension of the scaffold is maximum, greater than or equal to 2 cm.
US Pat. No. 10,688,474

CATALYST FOR DEHYDROGENATION REACTION OF FORMATE AND HYDROGENATION REACTION OF BICARBONATE AND PREPARATION METHOD THEREOF

Korea Institute of Scienc...

1. A catalyst for a dehydrogenation reaction of formate and a hydrogenation reaction of bicarbonate, the catalyst comprising:a polyaniline-based porous carbon support, in which palladium particles are fixed,
wherein the catalyst further comprises a region in which nitrogen is included, and
wherein the catalyst has a specific surface area of 500 to 1,200 (m2·g?1).
US Pat. No. 10,689,500

HIGH MOLECULAR WEIGHT POLYSTYRENE IN INKS AND COATINGS

Sun Chemical Corporation,...

1. An ink or coating composition comprising a depolymerized polystyrene resin deriving from a source polystyrene resin, the depolymerized polystyrene resin having a number average molecular weight equal to or greater than 5,000 Dalton; and further comprising one or more of a colorant, an energy-curable component, and a photoinitiator.
US Pat. No. 10,688,475

CATALYSED SUBSTRATE MONOLITH

Johnson Matthey Public Li...

1. A substrate monolith comprising:a first washcoat comprising a catalyst material disposed on a first support material, wherein the catalyst material comprises at least one platinum group metal; and
a second washcoat comprising a metal that is either Pd or a mixture or alloy comprising Au and Pd, wherein the metal supported on a second support material comprising zirconia;
wherein the second washcoat is adjacent to the first washcoat and arranged to contact the exhaust gas after the exhaust gas has contacted the catalytic material; and
wherein the first and second support materials are different metal oxides.
US Pat. No. 10,689,501

COMPOSITE POLYESTER MATERIAL, COMPOSITE POLYESTER FIBER, PROCESSES FOR PREPARING THE SAME AND USES THEREOF

Jinan Shengquan Group Sha...

1. A composite polyester material comprising:a composite having a carbon nanostructure comprising:
carbon element;
a first non-carbon non-oxygen element substance from 0.5 to 4 wt% of the composite having the carbon nanostructure, the first non-carbon non-oxygen element substance consisting essentially of P, Si, Ca, Al and Na; and
a second non-carbon non-oxygen element from 0 to 4 wt% of the composite having the carbon nanostructure, the second non-carbon non-oxygen element is any one selected from the group consisting of Fe, Ni, Mn, K, Mg, Cr, S or Co, or a combination of at least two selected therefrom;
wherein the G peak and D peak of the carbon element in the Raman spectrum has a D peak to G peak height ratio of 1-20 in the composite having the carbon nanostructure, and optionally, the composite having the carbon nanostructure further has a 2D peak in the Raman spectrum;
wherein the composite having the carbon nanostructure is present in the composite polyester material in an amount of 0.1-10 wt%.
US Pat. No. 10,688,220

AMNIOTIC MEMBRANE

THE UNIVERSITY OF NOTTING...

1. A method of processing an amniotic membrane to provide a vacuum-dried amniotic membrane comprising the step of vacuum-drying the amniotic membrane, wherein the membrane is not frozen before or during the vacuum-drying step, and wherein when the membrane is reconstituted the membrane preparation releases epidermal growth factor (EGF) for a period of two or more days.
US Pat. No. 10,689,502

PROCESSES FOR PREPARING CABLES WITH A CROSSLINKED INSULATION LAYER AND CABLES FOR SAME

Dow Global Technologies L...

1. A process for preparing a degassed cable core having a crosslinked insulation layer, said process comprising:(a) providing an initial cable core comprising:
(i) a conductor;
(ii) a first polymeric semiconductive layer;
(iii) an initial insulation layer comprising a crosslinkable polymeric composition which comprises an ethylene-based polymer, an organic peroxide, an antioxidant, and a polyallyl crosslinking coagent;
(iv) a second polymeric semiconductive layer;
(b) subjecting said initial cable core to a crosslinking process sufficient to crosslink at least a portion of said crosslinkable polymeric composition to thereby produce said cable core having a crosslinked insulation layer, and
(c) subjecting said cable core having a crosslinked insulation layer to a degassing process at a degassing temperature, a degassing pressure, and for a degassing time period to produce a degassed cable core,
wherein said polyallyl crosslinking coagent and said organic peroxide are present in said crosslinkable polymeric composition in amounts sufficient to provide an allyl-to-active oxygen molar ratio of less than 1.2, based on the allyl content of said polyallyl crosslinking coagent and the active oxygen content of said organic peroxide,
wherein said crosslinkable polymeric composition exhibits at least 25% less coagent sweat out in parts per million (ppm) when stored at 23° C. for a period of two weeks relative to coagent sweat out in ppm of a reference crosslinkable polymeric composition which has the same composition as said crosslinkable polymeric composition except that said reference crosslinkable polymeric composition has an allyl-to-active oxygen molar ratio of 1.2, wherein sweat out is determined using pelletized samples according to Sweat Out procedure,
wherein said crosslinkable polymeric composition exhibits at least 5% less antioxidant sweat out in parts per million (ppm) and at least 10% less organic peroxide sweat out in ppm when stored at 23° C. for a period of two weeks relative to antioxidant sweat out in ppm and organic peroxide sweat out in ppm, respectively, of a reference crosslinkable polymeric composition which has the same composition as said crosslinkable polymeric composition except that said reference crosslinkable polymeric composition has an allyl-to-active oxygen molar ratio of 1.2, wherein sweat out is determined using pelletized samples according to Sweat Out procedure,
wherein when said crosslinked insulation layer is subjected to a degassing process at 70° C. and standard pressure, said crosslinked insulation layer exhibits a reduction in degassing time of at least 50% to reach a methane content of 200 ppm relative to a reference crosslinked insulation layer having the same composition except that the reference crosslinked insulation layer contains no polyallyl crosslinking coagent and twice the amount of organic peroxide on a weight basis.
US Pat. No. 10,688,221

HUMAN LIVER SCAFFOLDS

UCL BUSINESS PLC, London...

1. A method of producing a decellularized human liver scaffold comprising(i) providing healthy or pathological human liver tissue comprising a whole liver or a functional unit thereof,
(ii) mechanically damaging the cells in the tissue,
(iii) subjecting the cells in the tissue to osmotic stress by exposing the tissue to a hypotonic reagent or hypertonic reagent,
(iv) exposing the tissue to a protease and/or DNAase, and
(v) exposing the tissue to a detergent, and
(vi) repeating steps (iii) to (v) in the following sequence by perfusion through the liver tissue: (iii), (iv), (iii), (iv), (v), [(iii), (v)]n, optionally [(iii), or (iv)], [(iii), (v)]n, where n is independently 1 to 25;
thereby producing a decellularized human liver scaffold,
wherein the human liver tissue is subjected to flow shear stress generated by perfusing the human liver tissue in a retrograde direction with the hypotonic reagent, hypertonic reagent, protease and/or DNAase, and detergent during steps (iii) to (vi) at a perfusion rate which increases from an initial value of 0.1-1.99 ml/min/gram of tissue and stabilizes to a target value of 2-20 ml/min/gram of tissue.
US Pat. No. 10,689,505

MICROSPHERES

Merck Patent GmbH, Darms...

1. A microsphere comprising core/shell particles dispersed in apolyolefin carrier matrix,
wherein
said core of the core/shell particles comprises,
an absorber which is a mixture consisting of Bi2O3 and TiO2 (Bi2O3/TiO2),
a film former which comprises PPO/PS or PBT,
and
said shell of the core/shell particles comprises
at least one compatibilizer that is a grafted polyolefin, ethylene-GMA or styrene-ethylene-butylene-styrene (SEBS),
wherein the D50 value for TiO2 is in the range of 0.02-5 ?m
and
wherein said microsphere comprises
25-70% by weight of the Bi2O3/TiO2,
8-25% by weight of the PPO/PS or PBT,
0.5-7.5% by weight of grafted polyolefin, ethylene-GMA or SEBS compatibilizer,
20-50% by weight of the polyolefin carrier matrix, and may also comprise
0-5% by weight of additives,
based on the microsphere, where the % by weight add up to ?100%.
US Pat. No. 10,688,224

PROSTHETIC IMPLANTABLE ANTIBACTERIAL SURGICAL MESH

King Abdulaziz University...

1. An implantable medical prosthetic mesh having nanofibers deposited on the surface of a mesh substrate, wherein the nanofibers comprise:chitosan in an amount in the range of 8 wt. % to 35 wt. %, the chitosan having a degree of deacetylation in a range of 70% to 95%;
an antibiotic in an amount in the range of 15 wt. % to 35 wt. %; and
a polymer blend in an amount in the range of 45 wt. % to 70 wt. %, each weight percent relative to a total weight of the nanofibers;
wherein the polymer blend comprises polyvinyl alcohol and polyvinylpyrrolidone;
wherein the nanofibers are formed by
mixing a first solution of chitosan with a second solution of the antibiotic and the polymer blend to form a solution mixture, and
electrospinning the solution mixture to form the nanofibers,
wherein an average diameter of the nanofibers is in a range of 50 nm to 300 nm,
wherein the nanofibers have a bore size in a range of 300 nm to 900 nm,
wherein the antibiotic is released from the nanofibers steadily for at least 14 days, and
wherein the implantable medical prosthetic mesh has an antibiotic release rate in a range of 0.01 ?g/(cm2·min) to 10 ?g/(cm2·min).
US Pat. No. 10,688,480

EXHAUST GAS-PURIFYING COMPOSITION

1. An exhaust gas purification method comprising purifying exhaust gas emitted from a gasoline engine by using a composition comprising BEA zeolite which has an SiO2/Al2O3 molar ratio of greater than 25 and 600 or less and which contains phosphorus and zirconium, wherein an amount of the phosphorus contained in the zeolite is such that a molar ratio (P/Al) thereof with respect to Al in the BEA zeolite is 0.5 or greater, an amount of the zirconium contained in the zeolite is such that a molar ratio (Zr/Al) thereof with respect to Al in the zeolite is 0.5 or greater, and the BEA zeolite which contains phosphorus and zirconium has a Zr—O—P bond.
US Pat. No. 10,689,506

RESIN COMPOSITION AND RESIN MOLDED BODY

EASTMAN CHEMICAL COMPANY,...

1. A resin composition comprising:cellulose acetate (A) having a degree of substitution of about 2.1 or more and about 2.6 or less;
a plasticizer (B);
a polyhydroxyalkanoate (C); and
an olefin-(meth)acrylate copolymer (D).
US Pat. No. 10,689,507

RUBBER COMPOSITION COMPRISING A STYRENE-BUTADIENE COPOLYMER HAVING A LOW GLASS TRANSITION TEMPERATURE, AND A HIGH CONTENT OF FILLER AND OF PLASTICIZER

COMPAGNIE GENERALE DES ET...

1. A rubber composition based on:100 phr (parts by weight per hundred parts by weight of elastomer) of a low-Tg styrene/butadiene elastomer, the glass transition temperature Tg of which is less than ?60° C.;
145 to 155 phr of reinforcing filler;
115 to 130 phr in total of a plasticizing system comprising a hydrocarbon-based resin at a content within a range extending from 85 to 90 phr and a plasticizing oil at a content within a range extending from 20 to 30 phr; and
a vulcanization system;
wherein the reinforcing filler comprises at least 130 phr of silica and 1 to 5 phr of carbon black.
US Pat. No. 10,689,508

RUBBER COMPOSITION AND PNEUMATIC TIRE USING SAME

The Yokohama Rubber Co., ...

1. A rubber composition comprising:a diene rubber component containing a styrene-butadiene copolymer component including at least one type of styrene-butadiene copolymer;
and a reinforcing filler,
wherein the styrene-butadiene copolymer component including the at least one type of styrene-butadiene copolymer has the following characteristics (1) to (4):
(1) a bonded styrene content is from 5 to 50 wt. %;
(2) among components obtained by ozone decomposition, a content of a decomposed component V1 containing one 1,2-bonded butadiene-derived unit out of a total of 100 mol % of decomposed components containing styrene-derived unit(s) and/or the 1,2-bonded butadiene-derived unit(s) is not less than 25 mol %;
(3) among components obtained by ozone decomposition, a content of a decomposed component S2V1 containing two styrene-derived units and one 1,2-bonded butadiene-derived unit out of a total of 100 mol % of decomposed components containing styrene-derived units and/or 1,2-bonded butadiene-derived units is less than 5 mol %; and
(4) a vinyl content of a butadiene moiety is not less than 50%.
US Pat. No. 10,689,509

POWDER MOLDABLE VINYL CHLORIDE RESIN COMPOSITION FOR REAL-STITCHED SURFACE SKIN AND METHOD FOR PRODUCING THE SAME, VINYL CHLORIDE RESIN MOLDED PRODUCT FOR REAL-STITCHED SURFACE SKIN AND METHOD FOR PRODUCING THE SAME, AND LAMINATE

ZEON CORPORATION, Chiyod...

1. A powder moldable vinyl chloride resin composition for a real-stitched surface skin comprising:vinyl chloride resin particles (a) having an average degree of polymerization of at least 1,200 and no greater than 5,000 and an average particle diameter of at least 50 ?m and no greater than 500 ?m;
a trimellitate plasticizer (b);
vinyl chloride resin fine particles (c) having an average degree of polymerization of greater than 2500 and no greater than 5,000 and an average particle diameter of at least 0.1 ?m and no greater than 10 ?m,
vinyl chloride resin fine particles (d) having an average degree of polymerization of less than 1,000 and an average particle diameter of at least 0.1 ?m and no greater than 10 ?m, and
a polar group-modified silicone oil (e),
wherein an amount of the trimellitate plasticizer (b) relative to 100 parts by mass, in total, of the vinyl chloride resin particles (a), the vinyl chloride resin fine particles (c), and the vinyl chloride resin fine particles (d) is at least 70 parts by mass and no greater than 200 parts by mass,
an amount of the vinyl chloride resin fine particles (c) relative to 100 mass %, in total, of the vinyl chloride resin particles (a), the vinyl chloride resin fine particles (c), and the vinyl chloride resin fine particles (d) is at least 3 mass % and no greater than 20 mass %, and
an amount of the vinyl chloride resin fine particles (d) relative to 100 mass %, in total, of the vinyl chloride resin particles (a), the vinyl chloride resin fine particles (c), and the vinyl chloride resin fine particles (d) is at least 2 mass % and no greater than 15 mass %.
US Pat. No. 10,689,510

NANOPARTICLE-POLYMER FLUORESCENT COMPOSITE AND METHOD OF PREPARING THE SAME

Korea University Research...

1. A method of preparing a nanoparticle-polymer fluorescent composite, the method comprising:preparing magnetite (Fe3O4) nanoparticles;
mixing the magnetite (Fe3O4) nanoparticles, an organic polymer having an aliphatic carbon chain, and a solvent for dissolving the organic polymer to prepare a preliminary composite and drying the preliminary composite to form a nanoparticle polymer composite; and
irradiating a pulse laser to the nanoparticle polymer composite to change the magnetite (Fe3O4) nanoparticles to Wustite nanoparticles and providing conjugated polymer characteristics to the organic polymer.
US Pat. No. 10,688,743

METHOD FOR THE TREATMENT OF A SEALANT LAYER OF A TYRE, SEALANT AND TYRE

BRIDGESTONE CORPORATION, ...

1. A method for the application of a sealant layer in a tire comprising a deposition step, in which a vulcanized sealant layer having a stickiness is deposited on a free surface of an inner liner layer facing an inner cavity of the tire; and a step of reduction of the stickiness, in which a surface exposed to the air of said sealant layer deposited on said inner liner layer is subject to the direct action of a UV radiation.
US Pat. No. 10,689,255

METHOD FOR RECOVERING AND PURIFYING WASTE SULFURIC ACID SOLUTION

Xiangtan University, Xia...

1. A method for recovering and purifying a waste sulfuric acid solution, comprising steps of:S1: adding a coupling agent (m) to the waste sulfuric acid solution, and mixing uniformly to obtain a mixture (a);
S2: adding a coupling agent (n) to the mixture (a), and mixing uniformly to obtain a mixture (b); and
S3: adding a synergistic agent to the mixture (b), thoroughly stirring and filtering to obtain a purified sulfuric acid solution.
US Pat. No. 10,689,769

ELECTRODEPOSITED LEAD COMPOSITION, METHODS OF PRODUCTION, AND USES

Aqua Metals Inc., Alamed...

1. A method of forming a lead structure, comprising:providing a lead composite comprising solid metallic lead having a purity of at least 98 mol %, molecular hydrogen, and a solvent, wherein the solid metallic lead, the hydrogen, and the solvent form a micro- or nanoporous mixed matrix comprising less than 0.10 weight % lead oxides;
introducing the lead composite into a structured mold;
cold-forming the lead structure in the mold at a temperature below a melting temperature of lead; and
removing at least some of the solvent and the molecular hydrogen from the lead composite during or before the cold-forming of the lead structure in the mold;
wherein the lead composite further comprises a guest compound, wherein the guest compound is a metal in elemental form or a carbon allotrope, or wherein the guest compound is selected from the group consisting of metallic copper, metallic nickel, metallic magnesium, metallic tin, metallic calcium, a graphene, and a fullerene.
US Pat. No. 10,687,976

HYDROPHILIC POLYMER COATINGS WITH DURABLE LUBRICITY AND COMPOSITIONS AND METHODS THEREOF

HydroGlyde Coatings LLC, ...

1. A method for manufacturing a condom, comprising:providing a sheath of an elastomeric material selected from natural or synthetic rubber latex, the sheath having an outer surface and an inner surface;
depositing a first layer of an aqueous suspension of a latex polymer to at least a portion of the outer surface of the sheath;
curing the latex polymer with exposure to heat for a time sufficient to form a first or base layer of cured latex polymer;
depositing a second layer of a composition, comprising a hydrophilic polymer and a suspension of latex polymer, to at least a portion of the first or base layer; and
curing the second layer of hydrophilic polymer and latex polymer with exposure to heat for a time sufficient to form a second or top layer,whereinthe hydrophilic polymer has a mean molecular weight in the range from about 1 kDa to about 1,000 kDa and is present in the composition at a concentration from about 2 w/v % to about 10 w/v %;
the latex polymer microparticles are present in the composition at a concentration from about 20 w/v % to about 60 w/v %; and
the weight ratio of the hydrophilic polymer to the latex polymer microparticles is in the range from about 1:1 to about 10:1.
US Pat. No. 10,688,494

MICROFLUIDIC SURFACE-MEDIATED EMULSION STABILITY CONTROL

10X Genomics, Inc., Plea...

1. A microfluidic emulsion droplet generation system comprising:a) a microfluidic substrate having a flow path configured and arranged for emulsion droplet generation;
b) at least one channel junction in the flow path for emulsion droplet formation; and
c) a reservoir in the flow path downstream of the channel junction comprising at least one textured surface configured and arranged for inducing surface-mediated coalescence of a plurality of emulsion droplets.
US Pat. No. 10,689,520

MODIFIED MINERAL-BASED FILLER COMPRISING COPPER SALTS

Omya International AG, O...

1. A process for manufacturing a modified mineral-based filler with antimicrobial activity comprising the following steps:(i) providing at least one alkaline earth metal carbonate-comprising material, wherein said alkaline earth metal carbonate-comprising material is ground calcium carbonate or dolomite, or mixtures thereof,
(ii) providing at least one water soluble copper salt selected from copper nitrate, copper sulphate, copper acetate, copper chloride, copper bromide, hydrates thereof, and any mixture thereof, and wherein the at least one water soluble copper salt is added in an amount from 0.01 to 3 wt.-%, based on the total weight of the at least one alkaline earth carbonate-comprising material,
(iii) contacting the at least one alkaline earth metal carbonate-comprising material of step (i), the at least one water soluble copper salt of step (ii), and optionally water, in one or several steps to form a mixture,
(iv) heating the mixture obtained from step (iii) to a temperature in the range from 70 to 140° C.,
(v) optionally separating the modified mineral-based filler from an aqueous suspension obtained from step (iv), and
(vi) drying until the moisture content of the modified mineral-based filler is less than or equal to 1.0 wt.-%, based on the total weight of the dried modified mineral-based filler.
US Pat. No. 10,688,239

METHOD FOR EXTRACORPOREAL REMOVAL OF A PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

ExThera Medical Corporati...

1. A method for treating a subject in need thereof, by extracorporeal removal of a pathogenic microbe, said method comprising:a) contacting said subject's whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said pathogenic microbe in said subject's whole blood sample to the heparin;
b) separating the whole blood from the solid substrate;
c) recovering said whole blood containing a reduced amount of said pathogenic microbe; and
d) reintroducing into said subject said whole blood containing a reduced amount of said pathogenic microbe.
US Pat. No. 10,689,521

LOW DENSITY UV-CURABLE OPTICAL FIBER COATING, FIBER MADE THEREWITH, AND METHOD OF FIBER MANUFACTURE

OFS FITEL, LLC, Norcross...

1. A composition for coating an optical fiber comprising:a free radically curable acrylate and/or a methacrylate functionalized oligomer having a density of less than 1.0 g/cm3; where the acrylate and/or the methacrylate functionalized oligomer has a functionality of 1 or more;
a photoinitiator; and
optionally a free radically curable acrylate and/or methacrylate diluent monomer that has a density of less than 1.0 g/cm3; where the coating composition is disposed and cured on an optical fiber; where the density of the cured coating is less than 1.0 g/cm3; and where the average functionality of the composition is greater than one; where a cured coating manufactured from the composition has an elastic modulus at 23° C. of 0.3 to 100 megapascals.
US Pat. No. 10,688,753

LAMINATED POLYARYLENE SULFIDE HEAT-RESISTANT FILTER

Toray Industries, Inc., ...

1. A laminated polyarylene sulfide heat-resistant filter comprising a plurality of layers, at least including a first web layer that is a filtering surface, and a second web layer that is a non-filtering surface, whereinthe first web layer consists of 30 to 70 wt % of polyarylene sulfide fibers having a fineness of 0.5 to 1.2 dtex, and 30 to 70 wt % of polyarylene sulfide fibers having a fineness of 1.3 to 3.0 dtex, based on a total of a weight percentages of the first web layer as 100 wt %, and
the second web layer consists of polyarylene sulfide fibers having a fineness of 1.0 to 4.0 dtex.
US Pat. No. 10,688,500

SYSTEMS AND METHOD FOR REMOVAL OF ACID GAS IN A CIRCULATING DRY SCRUBBER

Mississippi Lime Company,...

1. A method for removal of sulfur dioxide (SO2) from a flue gas, the method comprising:providing a flue gas duct including a circulating dry scrubber (CDS); and
injecting a particulate lime hydrate having into said CDS;
wherein:
said particulate lime hydrate has a D90 particle size less than or equal to 10 microns;
the particulate lime hydrate has a D50 particle size of less than or equal to 4 microns;
the particulate lime hydrate has a D90/D50 particle size distribution of less than 3; and
the particulate lime hydrate has a BET surface area of 18 m2/g or greater.
US Pat. No. 10,689,526

N-HALAMINES COMPOUNDS AS MULTIFUNCTIONAL ADDITIVES

Board of Regents, The Uni...

1. A biofilm-controlling and photo and thermal stabilizing additive comprising:a sterically hindered N-halo-amine comprising a 2,2,6,6-tetramethyl-N-halo-piperidinyl ring moiety directly connected to an aliphatic chain, with a molecular weight higher than 200 g/mol, wherein the 2,2,6,6-tetramethyl-N-halo-piperidinyl ring moiety does not include a spirocyclic group, and
wherein the composition provides anti-biofilm and thermal and photo stabilizing function.
US Pat. No. 10,689,782

TEXTILE FABRIC FABRICATED OF TWILL WEAVE SHEETING

1. A textile fabric comprising: a twill weave sheeting comprising a first surface and a second opposite surface,wherein the twill weave sheeting comprises:
a 100% cotton warp yarn with a yarn count of 40 s to 60 s;
a 100% polyester weft yarn with a denier of 15 D to 19 D and 7 to 28 filaments;
wherein the cotton warp yarn and the polyester weft yarn in each surface are a weave, 2 over and 1 under;
wherein both the first and second surfaces comprise a proportion of cotton and a proportion of polyester, the proportion of cotton being greater than the proportion of polyester; and
wherein the twill weave sheeting has a high thread count of 200 to 2000 threads per square inch.
US Pat. No. 10,693,115

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY SEPARATOR

SUMITOMO CHEMICAL COMPANY...

1. A nonaqueous electrolyte secondary battery separator comprising a polyolefin porous film,the nonaqueous electrolyte secondary battery separator having ion permeability barrier energy of not less than 300 J/mol/?m and not more than 900 J/mol/?m per unit film thickness,
wherein the nonaqueous electrolyte secondary battery separator causes an electrode resistance increasing rate after 100 charge-discharge cycles of a nonaqueous electrolyte secondary battery containing the nonaqueous electrolyte secondary battery separator to be lower than an electrode resistance increasing rate after 100 charge-discharge cycles of a nonaqueous electrolyte secondary battery containing a reference nonaqueous electrolyte secondary battery separator comprising a polyolefin porous film and having an ion permeability battery energy of less than 300 J/mol/?m or more than 900 J/mol/?m per unit film thickness,
wherein the electrode resistance increasing rate after 100 charge-discharge cycles is measured by subjecting the nonaqueous electrolyte secondary battery to 100 charge-discharge cycles each performed at 55° C. at a voltage ranging from 2.7 V to 4.2 V with CC-CV charge at a charge current value of 1 C, terminal current condition 0.02 C and with CC discharge at a discharge current value of 10 C,
wherein CC-CV is a charging method comprising charging the battery at a constant electric current to a certain voltage and maintaining the certain voltage while the electric current is reduced; and
wherein CC discharge is a discharging method comprising discharging the battery at a constant electric current until the certain voltage is reached.
US Pat. No. 10,689,528

HIGH PERFORMANCE SILICON BASED THERMAL COATING COMPOSITIONS

Burning Bush Group, LLC, ...

1. A silicon-based coating composition, comprising:8% to 30% (w/w of the total composition) polysilazane,
8% to 22% (w/w of the total composition) polysiloxane, and
30% to 45% (w/w of the total composition) high temperature silicone-based resin with a resistance up to 1200° F.,
which composition after curing is a thermal barrier coating that can withstand temperature over 1600° F. in accordance with ASTM E1530 test standards for heat stability, having a thickness ranging between about 0.4 mil and about 1.5 mil and a hardness ranging between about 4H and about 9H.
US Pat. No. 10,689,529

PIGMENTS FOR FILTERING THE SOLAR SPECTRUM

SUN CHEMICAL CORPORATION,...

1. A transparent coating system for light filtering between 400-2500 nm, comprised of a transparent polymeric binder, one or more pearlescent pigments, and one or more absorption pigments selected from organic pigments, organic pigment derivatives and/or inorganic pigments, having a total pigment loading; in a wet film, of between about 0.5%-20%, by weight; andwherein
a. TSR of the pigment blend between the wavelengths of about 400 nm-2500 nm, is in the range of about 40%-85%; and
b. TST of the pigment blend between the wavelengths of about 400 nm-2500 nm, is in the range of about 40%-85%; and
wherein the ratio of the
percent transmission at 660 nm to the percent transmission at 730 nm is in the range of about 0.5-2.0.
US Pat. No. 10,689,531

COATING COMPOSITION COMPRISING SUBMICRON CALCIUM CARBONATE-COMPRISING PARTICLES, PROCESS TO PREPARE SAME AND USE OF SUBMICRON CALCIUM CARBONATE-COMPRISING PARTICLES IN COATING COMPOSITIONS

Omya International AG, O...

1. A glossing and opacifying coating composition comprising an aqueous nanoparticle dispersion and at least one binder, wherein the nanoparticles have at least one of three dimensions that are less than 250 nm (D90) (Mal) that are substantially dispersed in the at least one binder and have a mean particle size D50 (Mal) of less than 1 micron, wherein the nanoparticles comprise ground calcium carbonate, wherein the at least one binder is selected from the group consisting of vinyl-acrylic, styrene-acrylic, acrylic dispersions, solution acrylics, polyurethanes dispersed either in water or solvent, polymers containing ester groups including polyesters, polyester-based polyurethanes, polyester-based polyureas and polyester-based polyamides and wherein the composition includes at least one pigment having a refractive index greater than or equal to 2.5.
US Pat. No. 10,688,763

DECORATIVE FILM AND DECORATIVE MOLDED BODY

FUJIFILM CORPORATION, To...

1. A decorative film comprising:a base film; and
a metal-containing layer which contains tabular metal particles, on one surface of the base film,
wherein the metal-containing layer further contains a binder resin and at least one of a polymerizable compound containing a radically polymerizable unsaturated group or a cured product of the polymerizable compound containing a radically polymerizable unsaturated group, and
wherein the polymerizable compound contains at least one selected from the group consisting of a polymerizable compound containing at least five ethylenically unsaturated groups, a urethane (meth)acrylate compound, ethoxylated bisphenol A diacrylate, tricyclodecanediol di(meth)acrylate and a polymerizable compound containing an alkylene oxide group having 2 or 3 carbon atoms.
US Pat. No. 10,687,482

METHOD OF PRODUCING FUNGAL MATERIALS AND OBJECTS MADE THEREFROM

Mycoworks, Inc., Emeryvi...

1. A method of growing fungal material, the method comprising the steps of:a. providing a nutritive vehicle having a mixture of nutrients and a fungal material distributed throughout;
b. growing fungal tissue from said nutritive vehicle, the fungal tissue comprising fungal hyphae;
c. extending fungal tissue growth directionally away from said nutritive vehicle and through a porous material defining an intermediate layer that does not readily bind with said fungal tissue and provides uniform initial conditions of growth thereby achieving uniform growth of the fungal tissue, wherein the porous material is micro-perforated or woven and is selected from the group consisting of metal, plastic, and ceramic plate,
d. causing a portion of said fungal tissue extending through the porous material away from said nutritive vehicle to grow into an enclosed administrable space having an environment, wherein the fungal tissue within said space defines at least one successive fungal material layer;
e. manipulating the growing fungal tissue by directing a change in the growth pattern of at least one of said fungal hyphae in at least one successive layer;
f. delaminating at least a portion of the fungal material from said nutritive vehicle by pulling the fungal material off the intermediate layer thereby promoting a continuous growth of the fungal material; and
g. altering through physical or chemical means only said portion of the fungal material.
US Pat. No. 10,689,534

AQUEOUS DRY-ERASABLE INK COMPOSITION

1. An aqueous dry-erasable ink composition comprising, water, composite pigment, one or more rheology additive, one or more wetting agent, one or more water-soluble resin, pH adjuster, and one or more water-soluble biocide selected from the group consisting of sodium sorbate, sodium 2-pyridinethiol-1-oxide and cetyltrimethylammonium bromide, wherein the one or more water-soluble biocide constitutes 0.005 wt % to 1.5 wt % of the total composition, wherein the pH of the composition is 4 to 12, and wherein the composite pigment is a compound of polymer resin and colored pigment at a weight ratio ranges from 10/90 to 97/3 and has an average particle size range from 20 ?m to 60 ?m.
US Pat. No. 10,693,123

POSITIVE ELECTRODE AND SECONDARY BATTERY USING SAME

NEC Corporation, Tokyo (...

1. A positive electrode comprising:a Mn composite oxide having a tetragonal structure (active material (3)) represented by the following formula (3):
LiaNixMn2-x-yAyO4  formula (3)
wherein in the formula (3), 1 a composite oxide having a layered structure (active material (2)) represented by
Li(LixM1-x-yYy)O2  formula (2)
wherein in the formula (2), 0?x<0.3, 0?y<0.3; M is at least one selected from the group consisting of Co, Fe, Ni and Mn; Y is at least one selected from the group consisting of Mg, Al, Zr, Ti and Zn.
US Pat. No. 10,687,486

SOYBEAN CULTIVAR S170116

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170116, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125448.
US Pat. No. 10,689,280

METHOD FOR THE REMOVING AND REDUCING SCALING

ECOLAB USA INC., St. Pau...

1. A method, comprising:adding an effective amount of a trimethylglycine composition into a water purification system comprising a membrane in order to reduce calcium phosphate scaling and scale buildup in the water purification system, wherein the trimethylglycine composition controls the initiation of the calcium phosphate scale nucleation, and mitigates its growth, wherein the trimethylglycine composition includes one or more of the following compounds selected from the group consisting of trimethylglycine hydrochloride and trimethylglycine-citric acid, wherein the trimethylglycine composition is put into the water purification system without the need for pH adjustment, and wherein the effective amount is between 0.2 ppm and 0.8 ppm.
US Pat. No. 10,687,487

SOYBEAN CULTIVAR S170121

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170121, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125450.
US Pat. No. 10,687,488

SOYBEAN CULTIVAR S170041

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170041, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125451.
US Pat. No. 10,688,770

METHODS FOR SOLID FREEFORM FABRICATION

RICOH CO., LTD., Tokyo (...

1. A system for printing a three-dimensional article, the system comprising:a solution of a prepolymer, wherein the prepolymer is a polysulfide, ketalized version of a polyketone, or a reduced form of a polyketone;
a printing mechanism for printing the solution of the prepolymer on a build plate to form a layer of the three-dimensional article; and
a printing controller to repeat the printing mechanism to print the solution of the prepolymer on a polymer formed by exposing the layer to a stimulus at a predetermined condition.
US Pat. No. 10,689,539

POLYESTER POLYMER HAVING PHENOLIC FUNCTIONALITY AND COATING COMPOSITIONS FORMED THEREFROM

The Sherwin Williams Comp...

1. A food or beverage can, or portion thereof, comprising:a body portion or an end portion comprising a metal substrate; and
a cured coating present on the metal substrate, wherein the cured coating is prepared from
a liquid coating composition comprising:
a polyesterpolymer having a structural unit represented by the schematic formula:-[BACKBONE SEGMENT]-,
LX-(CR1R2)n—Z
wherein:
-[BACKBONE SEGMENT]- depicts a segment of the backbone of the polyester polymer;
—X—(CR1R2)n—Z is a phenolic-containing pendant group;
X depicts an organic linking group connected to the backbone, wherein X includes an ester linkage;
Z depicts the phenolic group;
R1 and R2 are independently selected from a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkenyl group, or a null group; and
n?1; and
a liquid carrier; wherein the phenolic-containing group is selected from the group comprising of: p-hydroxphenyl acetic acid, p-hydroxypropinoic acid, diphenolic acid, alkyl esters thereof, or a mixture or derivative thereof.
US Pat. No. 10,687,489

SOYBEAN CULTIVAR S170065

M.S. Technologies, L.L.C....

1. A plant of soybean cultivar S170065, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-125452.
US Pat. No. 10,689,283

MANUFACTURING PROCESS FOR PREVENTING SHARDS OF HEAT-RESISTANT GLASSWARE FROM SCATTERING

HEBEI MSD GLASS TECHNOLOG...

1. A manufacturing process of heat-resistant glassware for preventing shards from scattering, comprising:(1) heating a heat-resistant glass tube to manufacture the heat-resistant glassware;
(2) performing annealing to remove stress: placing and rotating the heat-resistant glassware in an annealing furnace, wherein the annealing furnace comprises four sections, temperatures of the sections are sequentially 390° C., 480° C., 590° C., and 550° C., a rotational speed of the heat-resistant glassware is 415±15 rotations/minute, and a time that the heat-resistant glassware stays in each section is 25 minutes;
(3) performing thermal shock testing: placing the heat-resistant glassware in an oven, heating the heat-resistant glassware to 170° C., keeping the heat-resistant glassware at 170° C. for 15 minutes to 30 minutes, and then placing the heat-resistant glassware in water at a constant temperature of 20° C., keeping the heat-resistant glassware that has no crack or fracture for performing step (4);
(4) performing mechanical shock testing: knocking a body of the heat-resistant glassware with a steel ball with a weight of 3 oz, placing the heat-resistant glassware under a test fixture, and dropping the steel ball at a height of 76 mm from a test position vertically for impacting, wherein the test position comprises one inch below a rim of the heat-resistant glassware, a middle of and exterior of the heat-resistant glassware, one inch above a bottom of the exterior of the heat-resistant glassware, and a center of the bottom of the exterior of the heat-resistant glassware, keeping the heat-resistant glassware that has no break or crack for performing step (5); and
(5) first adding a diluent to a paint, stirring the diluent and the paint uniformly, wherein the diluent is naphtha, the paint is a silica paint, and a ratio of naphtha to the silica paint is 5 to 1, then adding a dedicated Karstedt's catalyst into the diluent and the paint obtaining a mixture of the naphtha, the silica paint and the Karstedt's catalyst, stirring the mixture uniformly, filtering the mixture with a small 250-mesh to 300 mesh filter, mechanical spraying the mixture onto the heat-resistant glassware, and baking the sprayed heat-resistant glassware for 10 minutes to 30 minutes at 180° C. to 220° C.
US Pat. No. 10,687,490

ALTERATION OF TOBACCO ALKALOID CONTENT THROUGH MODIFICATION OF SPECIFIC CYTOCHROME P450 GENES

North Carolina State Univ...

1. Cured tobacco material or a tobacco product comprising said cured tobacco material, wherein said cured tobacco material comprises a variant polynucleotide comprising a non-natural mutation as compared to the reference sequence SEQ ID NO: 4, and wherein said non-natural mutation is positioned between two sequences corresponding to SEQ ID NOs: 36 and 37 and wherein said polynucleotide comprises at least 95% sequence identity compared to SEQ ID NO:4.
US Pat. No. 10,689,541

COATINGS WITH WAX-MODIFIED HYPERBRANCHED AND FLEXIBLE HYPERBRANCHED POLYOLS

BASF COATINGS GMBH, Muen...

1. A coating composition comprising a wax-modified flexible hyperbranched polyol, wherein the wax-modified flexible hyperbranched polyol is prepared by a process comprising:(a) reacting a polyol comprising at least three hydroxyl groups with (a?) a C8-C85 linear or branched unsubstituted carboxylic acid and optionally with (a?) an aliphatic dicarboxylic acid having from 6 to 36 carbon atoms or an esterifiable derivative thereof, to form a hydroxyl-functional first intermediate product;
(b) reacting the hydroxyl-functional first intermediate product with a cyclic carboxylic acid anhydride to form a carboxylic acid-functional second intermediate product; and
(c) reacting the second intermediate product with an epoxide-functional compound having one epoxide group to form the wax modified flexible hyperbranched polyol.
US Pat. No. 10,689,797

METHOD FOR MANUFACTURING COMPOSITE FABRIC, COMPOSITE FABRIC, AND CARBON FIBER REINFORCED MOLDING

NITTA CORPORATION, Osaki...

1. A method for manufacturing a composite fabric, the method comprising:holding a surface of a filter part, through which a dispersion solvent and carbon nanotubes dispersed in the dispersion solvent are allowed to pass, in contact with at least one surface of a woven fabric comprising carbon fiber bundles as weaving yarn;
immersing the woven fabric on which the filter part is held in a dispersion that comprises the dispersion solvent and the carbon nanotubes dispersed in the dispersion solvent and applying ultrasonic vibrations to the dispersion; and
extracting the woven fabric on which the filter part is held from the dispersion and removing the filter part from the woven fabric.